<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">99344</article-id>
<article-id pub-id-type="doi">10.7554/eLife.99344</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99344.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.4</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Developmental Biology</subject>
</subj-group>
</article-categories><title-group>
<article-title>Loss of dihydroceramide desaturase drives neurodegeneration by disrupting endoplasmic reticulum and lipid droplet homeostasis in glial cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yuqing</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Kevin</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2468-9618</contrib-id>
<name>
<surname>Lacin</surname>
<given-names>Haluk</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>DiPaola</surname>
<given-names>Jose T</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Beth A</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patti</surname>
<given-names>Gary J</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Skeath</surname>
<given-names>James B</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<email>jskeath@wustl.edu</email>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Genetics, Washington University School of Medicine</institution></institution-wrap>, <city>St. Louis</city>, <country country="US">United States</country></aff>
<aff id="a2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Chemistry, Washington University in St. Louis</institution></institution-wrap>, <city>St. Louis</city>, <country country="US">United States</country></aff>
<aff id="a3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Medicine, Washington University School of Medicine</institution></institution-wrap>, <city>St. Louis</city>, <country country="US">United States</country></aff>
<aff id="a4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Center for Mass Spectrometry and Metabolic Tracing, Washington University in St. Louis</institution></institution-wrap>, <city>St. Louis</city>, <country country="US">United States</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01w0d5g70</institution-id><institution>Division of Biological and Biomedical Systems, University of Missouri-Kansas City</institution></institution-wrap>, <city>Kansas City</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Bellen</surname>
<given-names>Hugo J</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Baylor College of Medicine</institution>
</institution-wrap>
<city>Houston</city>
<country country="US">United States</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Cardona</surname>
<given-names>Albert</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Cambridge</institution>
</institution-wrap>
<city>Cambridge</city>
<country country="GB">United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="coi-statement"><p>Competing interests: G.J.P. has collaborative research agreements with Agilent Technologies and Thermo Scientific. G.J.P. is the chief scientific officer of Panome Bio. The remaining authors declare no competing interests.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-07-31">
<day>31</day>
<month>07</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-07-17">
<day>17</day>
<month>07</month>
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP99344</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-05-21">
<day>21</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-05-21">
<day>21</day>
<month>05</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.01.573836"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-07-31">
<day>31</day>
<month>07</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99344.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.99344.1.sa4">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99344.1.sa3">Reviewer #1 (Public Review):  </self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99344.1.sa2">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.99344.1.sa1">Reviewer #3 (Public Review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.99344.1.sa0">Author Response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Zhu et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhu et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-99344-v2.pdf"/>
<abstract>
<title>Abstract</title><p>Dihydroceramide desaturases convert dihydroceramides to ceramides, the precursors of all complex sphingolipids. Reduction of DEGS1 dihydroceramide desaturase function causes pediatric neurodegenerative disorder hypomyelinating leukodystrophy-18 (HLD-18). We discovered that <italic>infertile crescent (ifc)</italic>, the <italic>Drosophila DEGS1</italic> homolog, is expressed primarily in glial cells to promote CNS development by guarding against neurodegeneration. Loss of <italic>ifc</italic> causes massive dihydroceramide accumulation and severe morphological defects in cortex glia, including endoplasmic reticulum (ER) expansion, failure of neuronal ensheathment, and lipid droplet depletion. RNAi knockdown of the upstream ceramide synthase <italic>schlank</italic> in glia of <italic>ifc</italic> mutants rescues ER expansion, suggesting dihydroceramide accumulation in the ER drives this phenotype. RNAi knockdown of <italic>ifc</italic> in glia but not neurons drives neuronal cell death, suggesting that <italic>ifc</italic> function in glia promotes neuronal survival. Our work identifies glia as the primary site of disease progression in HLD-18 and may inform on juvenile forms of ALS, which also feature elevated dihydroceramide levels.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Key words</title>
<kwd><italic>DEGS1</italic></kwd>
<kwd>ceramide</kwd>
<kwd>sphingolipids</kwd>
<kwd>neurodegeneration</kwd>
<kwd>glia</kwd>
<kwd>lipid droplet</kwd>
<kwd>endoplasmic reticulum</kwd>
<kwd>leukodystrophy</kwd>
</kwd-group>
<funding-group>
<award-group id="funding-1">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>NS036570</award-id>
</award-group>
<award-group id="funding-1a">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>NS122903</award-id>
</award-group>
<award-group id="funding-1b">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>ES2028365</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>The revised manuscript is identical to the manuscript we have just submitted to eLife for final publication (aka: their version of record). In addition to minor text edits to increase readability of the manuscript, we added four new supplementary Figures (S3, S7, S8, and S14).</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Sphingolipids are key structural and functional components of the cell membrane in all eukaryotic cells and are enriched in glial cells, such as oligodendrocytes, where they comprise up to 30% of all membrane lipids.<sup><xref ref-type="bibr" rid="c1">1</xref></sup> All complex sphingolipids, like glycosylsphingolipids and sphingomyelin, derive from ceramide.<sup><xref ref-type="bibr" rid="c2">2</xref>–<xref ref-type="bibr" rid="c4">4</xref></sup> In the <italic>de novo</italic> ceramide biosynthesis pathway, dihydroceramide desaturases, such as DEGS1, produce ceramide from dihydroceramide by catalyzing the formation of a <italic>trans</italic> double bond between carbons 4 and 5 of the sphingoid backbone, which enhances conformational plasticity.<sup><xref ref-type="bibr" rid="c5">5</xref>,<xref ref-type="bibr" rid="c6">6</xref></sup> In humans, bi-allelic mutations in <italic>DEGS1</italic> cause hypomyelinating leukodystrophy-18 (HLD-18), a progressive, often fatal pediatric neurodegenerative disease marked by cerebral atrophy, white matter reduction, and hypomyelination.<sup><xref ref-type="bibr" rid="c7">7</xref>–<xref ref-type="bibr" rid="c9">9</xref></sup> The primary neural cell type impacted by loss of <italic>DEGS1</italic> function and the cell biology of how disruption of ceramide synthesis leads to neurodegeneration remain unknown.</p>
<p>The <italic>de novo</italic> ceramide biosynthetic pathway is well conserved among higher metazoans.<sup><xref ref-type="bibr" rid="c4">4</xref>,<xref ref-type="bibr" rid="c10">10</xref>–<xref ref-type="bibr" rid="c13">13</xref></sup> <italic>De novo</italic> ceramide synthesis occurs in the endoplasmic reticulum (ER) and starts with the rate-limiting activity of the serine palmitoyltransferase (SPT) complex, which condenses serine and palmitoyl-CoA (lauoryl-CoA in flies) to form 3-Ketosphinganine, which is converted to sphinganine by 3-Ketosphinganine reductase. Ceramide synthases condense sphinganine with acyl-CoA to generate dihydroceramide, which is converted to ceramide by dihydroceramide desaturases. Ceramide is then efficiently transported by the specific ceramide transporter CERT from the ER to the Golgi,<sup><xref ref-type="bibr" rid="c14">14</xref></sup> where it undergoes headgroup modifications to produce complex sphingolipids that eventually translocate to the plasma membrane.<sup><xref ref-type="bibr" rid="c15">15</xref></sup> Mutations in most members of the SPT complex, ceramide synthases, and DEGS1 lead to neurodegeneration,<sup><xref ref-type="bibr" rid="c4">4</xref>,<xref ref-type="bibr" rid="c12">12</xref>,<xref ref-type="bibr" rid="c13">13</xref></sup> identifying the <italic>de novo</italic> ceramide biosynthesis pathway as a hotspot for neurodegenerative disease mutations.</p>
<p>Consistent with its central role in ceramide biogenesis, reduction or loss of <italic>DEGS1</italic> function in human patients or cell lines, mice, zebrafish, and flies drive dihydroceramide accumulation and ceramide depletion.<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c16">16</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup> HLD-18 patients display reduced myelin sheath thickness in peripheral nerves, and knockdown of <italic>DEGS1</italic> function in zebrafish reduces the number of myelin basic protein-positive oligodendrocytes,<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref></sup> suggesting <italic>DEGS1</italic> regulates Schwann cell and oligodendrocyte development. In <italic>Drosophila</italic>, genetic ablation of <italic>infertile crescent</italic> (<italic>ifc</italic>), the fly <italic>DEGS1</italic> ortholog, drives activity-dependent photoreceptor degeneration,<sup><xref ref-type="bibr" rid="c17">17</xref></sup> suggesting that <italic>ifc</italic> function is crucial for neuronal homeostasis. In addition, forced expression of a wildtype <italic>ifc</italic> transgene in neurons, glia, or muscles was shown to rescue the <italic>ifc</italic> mutant phenotype.<sup><xref ref-type="bibr" rid="c17">17</xref></sup> Whether <italic>ifc/DEGS1</italic> acts primarily in glia, neurons, or other cells to regulate nervous system development then remains to be determined.</p>
<p>Research on <italic>DEGS1</italic> points to dihydroceramide accumulation as the driver of nervous system defects caused by <italic>DEGS1</italic> deficiency. Pharmacological or genetic inhibition of ceramide synthase function, which should reduce dihydroceramide levels, suppresses the observed reduction of MBP-positive oligodendrocytes in zebrafish and the activity-dependent photoreceptor degeneration in flies triggered by reduction of <italic>DEGS1/ifc</italic> function.<sup><xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup> Dihydroceramide accumulation may also contribute to other neurodegenerative diseases, as gain of function mutations in components of the SPT complex cause juvenile amyotrophic lateral sclerosis due to elevated sphingolipid biosynthesis, with dihydroceramides showing the greatest relative increase of all sphingolipids.<sup><xref ref-type="bibr" rid="c18">18</xref>–<xref ref-type="bibr" rid="c22">22</xref></sup> How dihydroceramide accumulation alters the cell biology of neurons, glia, or both to trigger myelination defects and neurodegeneration is unclear.</p>
<p>With its vast genetic toolkit, <italic>Drosophila</italic> is a powerful system in which to dissect the genes and pathways that regulate glial development and function.<sup><xref ref-type="bibr" rid="c23">23</xref>,<xref ref-type="bibr" rid="c24">24</xref></sup> In flies, six morphologically and functionally distinct glial subtypes regulate nervous system development and homeostasis.<sup><xref ref-type="bibr" rid="c25">25</xref>,<xref ref-type="bibr" rid="c26">26</xref></sup> The surface perineurial and subperineurial glia act as physiochemical barriers to protect the nervous system and control metabolite exchange with the hemolymph, carrying out a similar function as the human blood-brain-barrier.<sup><xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c28">28</xref></sup> Residing between the surface glia and the neuropil, cortex glia ensheathe the cell bodies of neuroblasts and neurons in the CNS in protective, nutritive, honeycomb-like membrane sheaths. Ensheathing glia define the boundary of the neuropil and insulate axons, dendrites, and synapses from neuronal cell bodies in the CNS.<sup><xref ref-type="bibr" rid="c29">29</xref></sup> Astrocyte-like glia extend fine membrane protrusions that infiltrate the neuropil and form a meshwork of cellular processes that ensheathe synapses and regulate synaptic homeostasis in the CNS.<sup><xref ref-type="bibr" rid="c29">29</xref></sup> In the PNS, wrapping glia reside internally to the surface glia and insulate axons in the PNS to enhance neuronal signaling and provide energy support.</p>
<p>Using the <italic>Drosophila</italic> model, we found that <italic>ifc</italic> acts primarily in glia to regulate CNS development with its loss disrupting glial morphology. Our work supports a model in which inappropriate accumulation and retention of dihydroceramide in the ER drives ER expansion, glial swelling, and the failure of glia to enwrap neurons, ultimately leading to neuronal degeneration as a secondary consequence of glial dysfunction. Given the conserved nature of <italic>de novo</italic> ceramide biosynthesis, our findings likely illuminate the exact mechanism through which elevated dihydroceramide levels drive neuronal degeneration and cell death in flies and humans.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title><italic>ifc</italic> contributes to the regulation developmental timing and CNS structure</title>
<p>In an EMS-based genetic screen, we uncovered three non-complementing mutations that when homozygous or trans-heterozygous to each other resulted in identical phenotypes, including a 3-day or greater delay in reaching the late-third larval instar stage, reduced brain size, progressive ventral nerve cord elongation, axonal swelling, and lethality at the late larval or early pupal stage (<xref rid="fig1" ref-type="fig">Figure 1A</xref>; data not shown). Whole genome sequencing revealed that <italic>ifc</italic> was independently mutated in each line: <italic>ifc<sup>js</sup></italic><sup><xref ref-type="bibr" rid="c1">1</xref></sup> and <italic>ifc<sup>js2</sup></italic> encode V276D and G257S missense mutations, respectively, and <italic>ifc<sup>js3</sup></italic> encodes a W162* nonsense mutation (<xref rid="fig1" ref-type="fig">Figures 1A</xref> and <xref rid="fig1" ref-type="fig">1B</xref>). Sanger sequencing also uncovered a missense mutation, E241K, in the molecularly uncharacterized <italic>ifc<sup>1</sup></italic> allele (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). All four mutations reside in the fatty acid desaturase domain, the hotspot for mutations in human <italic>DEGS1</italic> that cause HLD-18 (<xref rid="fig1" ref-type="fig">Figures 1B-B’</xref>).</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title><italic>ifc</italic> regulates CNS and glial morphology.</title> <p>A) Ventral views of late-third instar larvae of indicated genotype showing 3xP3 RFP labeling of CNS and nerves. Arrowheads indicate nerve bulges; scale bar is 200μm. B-B’) Schematic of Ifc (B) and human DEGS1 (B’) proteins indicating location and nature of <italic>ifc</italic> mutations and 15 HLD-18-causing <italic>DEGS1</italic> mutations.<sup><xref ref-type="bibr" rid="c7">7</xref>,<xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref></sup> C) Schematic of <italic>de novo</italic> ceramide biosynthesis pathway indicating the subcellular location of ceramide synthesis and ceramide modifications. D) Chemical structure of dihydroceramide and ceramide; arrow indicates <italic>trans</italic> carbon-carbon double bond between C4 and C5 in the sphingoid backbone created by the enzymatic action of Ifc/DEGS1. E) Normalized quantification of the relative levels of dihydroceramide, ceramide, and six related sphingolipid species in the dissected CNS of wild-type and <italic>ifc<sup>-/-</sup></italic> late-third instar larvae. F) Ventral views of <italic>Drosophila</italic> CNS and peripheral nerves in wild-type and <italic>ifc<sup>-/-</sup></italic> mutant late-third instar larvae labeled for NCAD to mark the neuropil, HRP to label axons, RFP to label glia, Dpn to label neuroblasts, ELAV to label neurons, and FABP to label cortex glia. Anterior is up; scale bar is 100μm for whole CNS images and 20μm for peripheral nerve image. Statistics: * denotes <italic>p</italic> &lt; 0.05, ** denotes <italic>p</italic> &lt; 0.01, *** denotes <italic>p</italic> &lt; 0.001, **** <italic>denotes p</italic> &lt; 0.0001.</p></caption>
<graphic xlink:href="573836v4_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>As a prior study reported that a CRISPR-generated, gene-specific deletion of <italic>ifc, ifc-KO,</italic> resulted in early larval lethality<sup><xref ref-type="bibr" rid="c17">17</xref></sup>, we first confirmed the genetic nature of our <italic>ifc</italic> alleles because they caused late larval-early pupal lethality. Complementation crosses of each <italic>ifc</italic> allele against a deficiency of the region (Df(2L)BSC184) and <italic>ifc-KO</italic> revealed that all combinations, including larvae trans-heterozygous for <italic>ifc-KO</italic> over Df(2L)BSC184, survived to the late larval-early pupal stage and yielded phenotypes identical to those detailed above for the newly uncovered <italic>ifc</italic> alleles. Flies homozygous for <italic>ifc-KO</italic>, however, died as early larvae. Further analysis uncovered second site mutation(s) in the 21E2 chromosomal region responsible for the early lethal phenotype of the <italic>ifc-KO</italic> chromosome (see Methods). When uncoupled from these mutation(s), larvae homozygous for the “clean” <italic>ifc-KO</italic> chromosome developed to the late larval-early pupal stage and manifested phenotypes identical to the other <italic>ifc</italic> alleles. This analysis defined the correct lethal phase for <italic>ifc</italic> and identified our <italic>ifc</italic> alleles as strong loss of function mutations.</p>
</sec>
<sec id="s2b">
<title>Loss of <italic>ifc</italic> function drives ceramide depletion and dihydroceramide accumulation</title>
<p>As <italic>ifc/DEGS1</italic> converts dihydroceramide to ceramide, we used untargeted lipidomics on whole larvae and the isolated CNS from wild-type and <italic>ifc-KO/ifc<sup>JS3</sup></italic> larvae (hereafter termed <italic>ifc<sup>-/-</sup></italic> larvae) to assess the effect of loss of <italic>ifc</italic> function on metabolites in the ceramide pathway (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Loss of <italic>ifc</italic> function resulted in a near complete loss of ceramides and a commensurate increase in dihydroceramides in the CNS and whole larvae (<xref rid="fig1" ref-type="fig">Figures 1E</xref>, <xref rid="figs1" ref-type="fig">S1</xref>). Sphinganine, the metabolite directly upstream of dihydroceramide, also exhibited a significant increase in its levels in the absence of <italic>ifc</italic> function, while metabolites further upstream were unchanged in abundance or undetectable (<xref rid="fig1" ref-type="fig">Figures 1E</xref>, <xref rid="figs1" ref-type="fig">S1</xref>). Ceramide derivatives like sphingosine, CPE, and Glucosyl-Ceramide (Glc-Cer), were reduced in levels and replaced by their cognate dihydroceramide forms (e.g., Glc-DiCer) (<xref rid="fig1" ref-type="fig">Figures 1E</xref>, <xref rid="figs1" ref-type="fig">S1</xref>). Loss of the enzymatic function of Ifc then drives dihydroceramide accumulation and ceramide loss.</p>
</sec>
<sec id="s2c">
<title><italic>ifc</italic> governs glial morphology and survival</title>
<p>To connect this metabolic profile to a cellular phenotype, we assayed <italic>ifc</italic> function in the CNS. We leveraged the expression of fatty acid binding protein (FABP) as a marker of cortex glia<sup><xref ref-type="bibr" rid="c30">30</xref></sup> and that of the <italic>M{3xP3-RFP.attP}</italic> phi-C31 “landing pad” transgene, which resided in the isogenic target chromosome of our screen, as a marker of most glia (<xref rid="figs2" ref-type="fig">Figures S2</xref> and <xref rid="figs3" ref-type="fig">S3</xref>). In addition, we labeled neuroblasts with Deadpan (Dpn), neurons with ELAV, and axons with N-Cadherin (NCad). In <italic>ifc</italic><sup>-/-</sup> larvae, we observed a clear reduction in Dpn-positive neuroblasts in the optic lobe, swelling of glia in peripheral nerves, enhanced RFP expression in the CNS, and the presence of large swollen, cortex glia identified by RFP labeling and fatty acid binding protein (FABP) expression (<xref rid="fig1" ref-type="fig">Figures 1F</xref>, <xref rid="figs4" ref-type="fig">S4</xref>, and <xref rid="figs5" ref-type="fig">S5</xref>). In wild-type larvae, cortex glia display compact cell bodies and fully enwrap individual neuronal cell bodies with their membrane sheaths (<xref rid="fig1" ref-type="fig">Figures 1F</xref> and <xref rid="figs4" ref-type="fig">S4</xref>).<sup><xref ref-type="bibr" rid="c30">30</xref></sup> In <italic>ifc</italic><sup>-/-</sup> larvae, cortex glia display swollen cell bodies, fail to fully enwrap neuronal cell bodies, displace neurons from their regular arrangement, and appear to contain brightly fluorescent RFP-positive aggregates (<xref rid="fig1" ref-type="fig">Figures 1F</xref>, <xref rid="figs6" ref-type="fig">S6</xref>). <italic>ifc</italic> is then necessary for glial development and function in the larval nervous system. We observed identical CNS phenotypes in larvae homozygous mutant for the <italic>ifc<sup>js1</sup></italic>and <italic>ifc<sup>js2</sup></italic> alleles (<xref rid="figs7" ref-type="fig">Figure S7</xref>).</p>
<p>To track the impact of <italic>ifc</italic> on glial morphology, we combined GAL4 lines specific for each glial subtype with a UAS-linked membrane-tagged GFP transgene (Myr-GFP) and the MultiColor FlpOut system.<sup><xref ref-type="bibr" rid="c31">31</xref>–<xref ref-type="bibr" rid="c33">33</xref></sup> Using this approach, we determined that loss of <italic>ifc</italic> function affects all CNS glial subtypes except perineurial glia (<xref rid="fig2" ref-type="fig">Figures 2E-E’</xref> and <xref rid="fig2" ref-type="fig">2J-J’</xref>). Cortex glia appeared swollen, failed to enwrap neurons, and accumulated large amounts of Myr-GFP<sup>+</sup> internal membranes (<xref rid="fig2" ref-type="fig">Figures 2A-A’</xref> and <xref rid="fig2" ref-type="fig">2F-F’</xref>). Ensheathing glia (<xref rid="fig2" ref-type="fig">Figures 2B-B’</xref> and <xref rid="fig2" ref-type="fig">2G-G’</xref>) and subperineurial glia (<xref rid="fig2" ref-type="fig">Figures 2D-D’</xref> and <xref rid="fig2" ref-type="fig">2I-I’</xref>) also displayed swollen, disorganized cell bodies and accumulated Myr-GFP<sup>+</sup> internal membranes. Astrocyte-like glia displayed smaller cell bodies, reduced membrane extensions, and disrupted organization along the dorsal ventral nerve cord (<xref rid="fig2" ref-type="fig">Figures 2C-C’</xref>). We conclude that <italic>ifc</italic> regulates the morphology of most glial subtypes in the larval CNS.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Loss of <italic>ifc</italic> disrupts glial morphology.</title> <p>A-E’) High magnification ventral views and X-Z and Y-Z projections of the nerve cord of wildtype and <italic>ifc<sup>-/-</sup></italic> late third instar larvae labeled for ELAV (magenta) for neurons and Myr-GFP (green) for cell membranes of indicated glial subtype. Anterior is up; scale bar is 40μm. F-J’) High magnification views of individual glial cells of indicated glial subtype in the nerve cord of wildtype and <italic>ifc<sup>-/-</sup></italic> larvae created by the MultiColor-FlpOut method.<sup><xref ref-type="bibr" rid="c33">33</xref></sup> Anterior is up; scale bar is 20μm. K-N) Quantification of total number of indicated glial subtype in the nerve cord of wildtype and <italic>ifc<sup>-/-</sup></italic> late third instar larvae (n = 7 for K, L, N; n = 6 for M). Statistics: * denotes <italic>p</italic> &lt; 0.05, **** denotes <italic>p</italic> &lt; 0.0001, and ns, not significant.</p></caption>
<graphic xlink:href="573836v4_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Next, we asked if loss of <italic>ifc</italic> function alters the number of each glial subtype. Using the same glial subtype-specific GAL4 lines to drive a nuclear-localized GFP transgene, we counted the total number of all CNS glial subtypes, except perineurial glia, in wild type and <italic>ifc<sup>-/-</sup></italic> larvae. To remove the small size of the brain in <italic>ifc<sup>-/-</sup></italic> larvae as a confounding factor, we focused our analysis on the ventral nerve cord. The number of subperineurial glia was unchanged between the two genotypes, but we observed a 12%, 40%, and 72% reduction in the number of astrocyte-like, ensheathing, and cortex glia, respectively, in <italic>ifc</italic><sup>-/-</sup> larvae relative to wild-type (<xref rid="fig2" ref-type="fig">Figures 2K-N</xref>). Our data reveal a broad role for <italic>ifc</italic> in regulating glial cell morphology and number in the <italic>Drosophila</italic> larval CNS. Subsequent experiments revealed that a reduction in cell proliferation and an increase in apoptosis both contribute to the observed reduction in the number of cortex glia (<xref rid="figs8" ref-type="fig">Figure S8</xref>).</p>
</sec>
<sec id="s2d">
<title><italic>ifc</italic> acts in glia to regulate glial and CNS development</title>
<p>Prior work in zebrafish showed that <italic>DEGS1</italic> knockdown reduced the number of myelin basic protein-positive oligodendrocytes;<sup><xref ref-type="bibr" rid="c9">9</xref></sup> in flies, loss of <italic>ifc</italic> function in the eye drove photoreceptor degeneration.<sup><xref ref-type="bibr" rid="c17">17</xref></sup> Neither study uncovered the cell type in which <italic>ifc/DEGS1</italic> acts to regulate neural development. To address this question, we used the GAL4/UAS system, RNAi-mediated gene depletion, and gene rescue approaches to see if <italic>ifc</italic> acts in neurons or glia to control glial development and CNS morphology. First, we used a UAS-linked <italic>ifc</italic>-RNAi transgene to deplete <italic>ifc</italic> function in all neurons (<italic>elav-GAL4</italic>; <italic>repo-GAL80</italic>) or all glia (<italic>repo-GAL4</italic>). Focusing on FABP-positive cortex glia due to their easily scorable phenotype, we found that pan-glial, but not pan-neuronal, knockdown of <italic>ifc</italic> recapitulated the swollen cortex glia phenotype observed in <italic>ifc</italic> mutant larvae (<xref rid="fig3" ref-type="fig">Figures 3C-D</xref> and <xref rid="fig3" ref-type="fig">3J</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title><italic>ifc</italic> acts in glia to regulate CNS structure and glial morphology.</title> <p>A-I) Ventral views of photomontages of the CNS of late third instar larvae labeled for FABP (greyscale) to mark cortex glia in late third instar larvae of indicated genotype. Neuronal-specific transgene expression was achieved by using <italic>elav-GAL4</italic> combined with <italic>repo-GAL80</italic>; glial-specific transgene expression was achieved by using <italic>repo-GAL4</italic>. J-K) Quantification of the number of swollen cortex glia in the abdominal segments of the CNS of late-third instar larvae of the indicated genotype for the RNAi (J) and gene rescue assays (K). Statistics: * denotes <italic>p</italic> &lt; 0.05, ** denotes <italic>p</italic> &lt; 0.01, *** denotes <italic>p</italic> &lt; 0.001, **** denotes <italic>p</italic> &lt; 0.0001, and ns, not significant.</p></caption>
<graphic xlink:href="573836v4_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To complement our RNAi approach, we asked if GAL4-driven expression of a wild-type <italic>Drosophila ifc</italic> or human <italic>DEGS1</italic> transgene rescued the <italic>ifc<sup>-/-</sup></italic> CNS phenotype. In the absence of a GAL4 driver, the <italic>ifc</italic> transgene drove weak rescue of the cortex glia phenotype (<xref rid="fig3" ref-type="fig">Figures 3E</xref> and <xref rid="fig3" ref-type="fig">3K</xref>), consistent with modest GAL4-independent transgene expression reported for UAS-linked transgenes.<sup><xref ref-type="bibr" rid="c34">34</xref></sup> Pan-neuronal expression of <italic>ifc</italic> drove modest rescue of the <italic>ifc</italic> CNS phenotype beyond that observed for the <italic>ifc</italic> transgene alone (<xref rid="fig3" ref-type="fig">Figures 3F</xref> and <xref rid="fig3" ref-type="fig">3K</xref>), but pan-glial expression of <italic>ifc</italic> fully rescued the <italic>ifc</italic> mutant cortex glia phenotype and other CNS phenotypes (<xref rid="fig3" ref-type="fig">Figures 3H, 3K</xref>, and <xref rid="figs9" ref-type="fig">S9</xref>). Identical experiments using the human <italic>DEGS1</italic> transgene revealed that only pan-glial <italic>DEGS1</italic> expression provided rescuing activity, albeit at much weaker levels than the <italic>Drosophila ifc</italic> transgene (<xref rid="fig3" ref-type="fig">Figures 3G, 3I</xref>, and <xref rid="fig3" ref-type="fig">3K</xref>). Pan-glial expression of the <italic>Drosophila ifc</italic> transgene was, in fact, ∼15-fold more potent than the human <italic>DEGS1</italic> transgene at rescuing the <italic>ifc</italic> lethal phenotype to adulthood: When <italic>ifc</italic> was expressed in all glia, 57.9% of otherwise <italic>ifc</italic> mutant flies survived to adulthood (n=2452), but when <italic>ifc</italic> was replaced by <italic>DEGS1</italic> only 3.9% of otherwise <italic>ifc</italic> mutant flies reached adulthood (n=1303). No <italic>ifc</italic> mutant larvae reached adulthood in the absence of either transgene (n=1030). We infer that <italic>ifc</italic> acts primarily in glia to govern CNS development and that human <italic>DEGS1</italic> can partially substitute for <italic>ifc</italic> function in flies despite a difference in the preferred length of the sphingoid backbone in flies versus mammals.<sup><xref ref-type="bibr" rid="c10">10</xref></sup></p>
<p>Results of our gene rescue experiments conflict with a prior study on <italic>ifc</italic> in which expression of <italic>ifc</italic> in neurons was found to rescue the <italic>ifc</italic> phenotype.<sup><xref ref-type="bibr" rid="c17">17</xref></sup> In this context, we note that <italic>elav-GAL4</italic> drives UAS-linked transgene expression not just in neurons, but also in glia at appreciable levels,<sup><xref ref-type="bibr" rid="c35">35</xref>, <xref ref-type="bibr" rid="c36">36</xref></sup> and thus needs to be paired with <italic>repo-GAL80</italic> to restrict GAL4-mediated gene expression to neurons. Thus, “off-target” expression in glial cells may account for the discrepant results. It is, however, more difficult to reconcile how neuronal or glial expression of <italic>ifc</italic> would rescue the observed lethality of the <italic>ifc-KO</italic> chromosome given the presence additional lethal mutations in the 21E2 region of the second chromosome.</p>
</sec>
<sec id="s2e">
<title><italic>ifc</italic> is predominately expressed in glia and localizes to the ER</title>
<p>Next, we tracked <italic>ifc</italic> expression in the CNS via RNA in-situ hybridization and an <italic>ifc-T2A-GAL4</italic> transcriptional reporter. RNA in-situ hybridization revealed that <italic>ifc</italic> is widely expressed in the CNS (<xref rid="fig4" ref-type="fig">Figure 4A</xref>), most obviously in the distinctive star-shaped astrocyte-like glia (<xref rid="fig4" ref-type="fig">Figure 4B</xref>), which are marked by Ebony expression.<sup><xref ref-type="bibr" rid="c37">37</xref></sup> RNA in-situ hybridization was not ideal for tracing <italic>ifc</italic> expression in other cells, likely due to signal diffusion. Thus, we paired the <italic>ifc</italic>-<italic>T2A-GAL4</italic> transcriptional reporter with a nuclear RFP (nRFP) transgene<sup><xref ref-type="bibr" rid="c38">38</xref></sup> and confirmed authenticity of the <italic>ifc-T2A-GAL4</italic> line by its strong expression in astrocyte-like glia (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). Using this approach, we observed strong nRFP expression in all glial cells (<xref rid="fig4" ref-type="fig">Figures 4D</xref> and <xref rid="figs10" ref-type="fig">S10A</xref>) and modest nRFP expression in all neurons (<xref rid="fig4" ref-type="fig">Figures 4E</xref> and <xref rid="figs10" ref-type="fig">S10B</xref>), suggesting <italic>ifc</italic> is transcribed at higher levels in glial cells than neurons in the larval CNS.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Loss of ifc drives ER expansion in cortex glia.</title> <p>A-E) Dorsal (A, B-B’’, and C-C’’) and ventral (D-D’’ and E-E’’) views of the CNS of late-third instar wild-type larvae labeled for <italic>ifc</italic> RNA (grey in A; magenta in B’), <italic>ifc-GAL4&gt;nRFP</italic> (magenta; C’-E’), EBONY to mark astrocytes (green; B and C), REPO to mark glia (green; D), and ELAV to mark neurons (green; E). Panels D-D’’ and E-E’’ show surface and interior views, respectively, along the Z-axis on the ventral side of the nerve cord. Arrowheads in E-E’’ identify neurons with low level <italic>ifc-GAL4</italic> expression. F-G) High magnification ventral views of thoracic segments in the CNS of wild-type late third instar larvae labeled for GFP (green; F and G), CNX99A (magenta; F’), ESYT (magenta; G’). H-M) Late third instar larvae of indicated genotype labeled for 3xP3-RFP (green; H’-M’), CNX99A (magenta; H and K), GOLGIN84 (magenta; I and L), and LAMP (magenta; J and M). Anterior is up; scale bar is 100μm for panel A and 30μm for panels B-M.</p></caption>
<graphic xlink:href="573836v4_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Using a fosmid transgene that harbors a GFP-tagged version of <italic>ifc</italic> flanked by ∼36-kb of its endogenous genomic region and molecular markers for ER, cis-Golgi, and trans-Golgi,<sup><xref ref-type="bibr" rid="c39">39</xref>–<xref ref-type="bibr" rid="c42">42</xref></sup> we found that the Ifc-GFP colocalized strongly with the ER markers Calnexin 99A (CNX99A) and ESYT (<xref rid="fig4" ref-type="fig">Figures 4F-F’, 4G-G’</xref>, and <xref rid="figs7" ref-type="fig">S7</xref>) and weakly with the cis-Golgi marker GOLGIN84 (<xref rid="figs10" ref-type="fig">Figure S10C</xref>) and the trans-Golgi marker GOLGIN245 (<xref rid="figs10" ref-type="fig">Figure S10D</xref>). Our results indicate that Ifc localizes primarily to the ER, aligning with the presumed site of <italic>de novo</italic> ceramide biosynthesis and prior work on <italic>DEGS1</italic> localization in cell lines.<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c43">43</xref></sup></p>
</sec>
<sec id="s2f">
<title>Loss of <italic>ifc</italic> drives ER expansion and lipid droplet loss in cortex glia</title>
<p>We next asked if loss of <italic>ifc</italic> function altered ER, Golgi, or lysosome morphology. Focusing on cortex glia, we observed a clear expansion of the ER marker CNX99A (<xref rid="fig4" ref-type="fig">Figures 4H-H’</xref> and <xref rid="fig4" ref-type="fig">K-K’</xref>), a mild enrichment of the Golgi markers, GOLGIN84 and GOLGIN245, in diffuse “clouds” (<xref rid="fig4" ref-type="fig">Figures 4I-I’, 4L-L’</xref>, <xref rid="figs10" ref-type="fig">S10E-F</xref>), and a reduction in expression of the lysosome marker LAMP (<xref rid="fig4" ref-type="fig">Figures 4J-J’</xref> and <xref rid="fig4" ref-type="fig">M-M’</xref>) in <italic>ifc<sup>-/-</sup></italic> larvae. The expansion of ER markers in <italic>ifc</italic> mutant larvae compelled us to obtain high-resolution views of organelle structure in cortex glia via transmission electron microscopy (TEM). In wildtype, cortex glia display a compact cytoplasm that surrounds a large nucleus (<xref rid="fig5" ref-type="fig">Figures 5A-B</xref>) and extend glial sheaths that fully enwrap adjacent neuronal cell bodies (black arrows; <xref rid="fig5" ref-type="fig">Figures 5C-D</xref>). In <italic>ifc<sup>-/-</sup></italic> larvae, cortex glia display enlarged cell bodies with a maze-like pattern of internal membranes (solid white arrows; <xref rid="fig5" ref-type="fig">Figures 5A’-B’</xref> and <xref rid="fig5" ref-type="fig">5E-E’</xref>) and fail to enwrap neurons (hollow white arrows; <xref rid="fig5" ref-type="fig">Figures 5C’-D’</xref>). The internal membrane structures appear to assume an ER-like identity, as we observed significant overlap between the ER marker CNX99A and the membrane marker Myr-GFP when Myr-GFP was driven by a cortex glia-specific GAL4 line (<xref rid="fig5" ref-type="fig">Figure 5F</xref>). We observed similar yet milder effects on cell swelling and internal membrane accumulation in subperineurial and wrapping glia in abdominal nerves (purple and pink shading, respectively; <xref rid="fig5" ref-type="fig">Figures 5G-G’</xref> and <xref rid="fig5" ref-type="fig">5H-H’</xref>), indicating that loss of <italic>ifc</italic> drives internal membrane accumulation in and swelling of multiple glial subtypes.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Loss of <italic>ifc</italic> leads to internal membrane accumulation and lipid droplet loss in cortex glia.</title> <p>A-E’) TEM images of cortex glia cell body (A-A’ and B-B’) and neuronal cell bodies (C-C’ and D-D’) at low (A-A’) and high (B-B’, C-C’, and D-D’) magnification in the nerve cord of wildtype (A-D) and <italic>ifc<sup>-/-</sup></italic> (A’-D’ and E-E’) late third instar larvae. (A-A’) Dotted lines demarcate cell boundary of cortex glia; yellow squares highlight regions magnified in B, B’, and E’. Scale bar is 3μm for A and A’ and 1μm for B-B’. (B-B’) Cy denotes cytoplasm; Nu denotes nucleus. Solid white arrows highlight the layered internal membranes that occupy the cytoplasm of <italic>ifc<sup>-/-</sup></italic> cortex glia. (C-C’ and D-D’) Black arrows highlight cortex glia membrane extensions that enwrap neuronal cell bodies; hollow white arrows denote the absence of cortex glia membrane extensions; white asterisk denotes lipid droplets. Scale bar is 2μm. E-E’) An additional example of membrane-filled cortex glia cell body in <italic>ifc<sup>-/-</sup></italic> larvae. Scale bar is 2μm for E and 1μm for E’. F) Cortex glia in <italic>ifc</italic> mutant larvae labeled for Myr-GFP (green) to label membranes and CNX99A to label ER membranes. Scale bar is 30μm. G-H) Black and white and colored TEM cross-sections of peripheral nerves in wild type and <italic>ifc<sup>-/-</sup></italic> late-third instar larvae. Blue marks perineurial glia; purple marks subperineurial glia; pink marks wrapping glia. Scale bar: 2μm. I-I’) High magnification ventral views of abdominal segments in the ventral nerve cord of wild-type (I) and <italic>ifc</italic> mutant (I’) third instar larvae labeled for BODIPY (green) to mark lipid droplets and FABP (magenta) to label cortex glia. Anterior is up; scale bar is 30μm. J) Graph of log-fold change of transcription of five genes that promote membrane lipid synthesis in <italic>ifc<sup>-/-</sup></italic> larvae relative to wildtype. Dotted line indicates a log2 fold change of 0.5 in the treatment group compared to the control group. -M) Quantification of the number (G) and area of lipid droplets (H and I) in the dissected CNS of wildtype and <italic>ifc<sup>-/-</sup></italic> larvae. Statistics: * denotes <italic>p</italic> &lt; 0.05, ** denotes <italic>p</italic> &lt; 0.01, *** denotes <italic>p</italic> &lt; 0.001, **** denotes <italic>p</italic> &lt; 0.0001, and ns, not significant.</p></caption>
<graphic xlink:href="573836v4_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>TEM analysis also revealed a near complete depletion of lipid droplets in the CNS of <italic>ifc</italic><sup>-/-</sup> larvae (compare <xref rid="fig5" ref-type="fig">Figures 5A, 5C</xref>, and <xref rid="fig5" ref-type="fig">5D</xref> to <xref rid="fig5" ref-type="fig">5A’, 5C’</xref> and <xref rid="fig5" ref-type="fig">5D’</xref>; lipid droplets marked by asterisk; <xref rid="fig5" ref-type="fig">Figure 5M</xref>), which we confirmed using BODIPY to mark neutral lipids in FABP-positive cortex glia (<xref rid="fig5" ref-type="fig">Figures 5I-L</xref>). In the CNS, lipid droplets form primarily in cortex glia<sup><xref ref-type="bibr" rid="c30">30</xref></sup> and are thought to contribute to membrane lipid synthesis through their catabolism into free fatty acids versus acting as an energy source in the brain.<sup><xref ref-type="bibr" rid="c44">44</xref></sup> Consistent with the possibility that increased membrane lipid synthesis drives lipid droplet reduction, RNA-seq assays of dissected nerve cords revealed that loss of <italic>ifc</italic> drove transcriptional upregulation of genes that promote membrane lipid biogenesis, such as <italic>SREBP</italic>, the conserved master regulator of lipid biosynthesis, <italic>SCAP</italic>, an activator of SREBP, and <italic>Pcyt1/Pcyt2,</italic> which promote phosphatidylcholine and phosphatidylethanolamine synthesis.<sup><xref ref-type="bibr" rid="c45">45</xref>–<xref ref-type="bibr" rid="c47">47</xref></sup> The spliced form of <italic>Xbp-1</italic> mRNA (<italic>Xbp-1s</italic>) (<xref rid="fig5" ref-type="fig">Figure 5J</xref>), which promotes membrane lipid synthesis required for ER biogenesis and is activated by the unfolded protein response (UPR),<sup><xref ref-type="bibr" rid="c48">48</xref></sup> is also upregulated in the CNS of <italic>ifc</italic> mutant larvae. Most ER chaperones, which are typically transcriptionally upregulated upon UPR activation,<sup><xref ref-type="bibr" rid="c49">49</xref></sup> were however downregulated (<xref rid="figs11" ref-type="fig">Figure S11A</xref>), suggesting that in this case misfolded protein is not the factor that triggers UPR activation and increased ER membrane biogenesis upon loss of <italic>ifc</italic>.</p>
</sec>
<sec id="s2g">
<title>Loss of <italic>ifc</italic> increases the saturation levels of triacylglycerols and membrane phospholipids</title>
<p>Lipid droplets are composed largely of triacylglycerols (TGs),<sup><xref ref-type="bibr" rid="c47">47</xref></sup> and we observed a 5-fold and 3-fold drop in TG levels in the CNS and whole larvae of <italic>ifc</italic> mutant larvae relative to wild-type (<xref rid="fig6" ref-type="fig">Figure 6A</xref>). Our lipidomics analysis also revealed a shift of TGs toward higher saturation levels in the absence of <italic>ifc</italic> function (<xref rid="fig6" ref-type="fig">Figures 6A-C</xref>). Consistent with this, we observed transcriptional upregulation of most genes in the Lands cycle, which remodels phospholipids by replacing existing fatty acyl groups with new fatty acyl groups (<xref rid="figs11" ref-type="fig">Figures S11B-C</xref>).<sup><xref ref-type="bibr" rid="c50">50</xref>–<xref ref-type="bibr" rid="c53">53</xref></sup> As TG breakdown results in free fatty acids that can be used for membrane phospholipid synthesis, we asked if changes in TG levels and saturation were reflected in the levels or saturation of the membrane phospholipids phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS). In the absence of <italic>ifc</italic> function, PC and PE exhibited little change in quantity (<xref rid="fig6" ref-type="fig">Figures 6D, 6G</xref>), but the levels of the less abundant PS were increased three-fold increase in the CNS of <italic>ifc</italic> mutant larvae relative to wild-type (compare <xref rid="fig6" ref-type="fig">Figure 6J</xref> to <xref rid="fig6" ref-type="fig">Figures 6D</xref> and <xref rid="fig6" ref-type="fig">6G</xref>). All three phospholipids, however, displayed increased saturation levels: The relative levels of all PC, PE, and PS species were reduced, except for the most saturated form of each phospholipid – 18:1/18:1 – which is increased (<xref rid="fig6" ref-type="fig">Figures 6E-F</xref> and <xref rid="fig6" ref-type="fig">6H-L</xref>). This increase was more pronounced in the CNS than whole larvae (<xref rid="fig6" ref-type="fig">Figures 6F, 6I</xref>, and <xref rid="fig6" ref-type="fig">6L</xref>), implying that loss of <italic>ifc</italic> function creates greater demand for lipid remodeling in the CNS.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>PC, PE, PS, and TG exhibit higher saturation levels in a CNS-specific manner in <italic>ifc</italic> mutant late third instar larvae.</title> <p>A-C) Quantification of total (A) and species-specific (B and C) TGs in whole larvae (A and C) and dissected CNS (A, B, and C) of wildtype and <italic>ifc<sup>-/-</sup></italic>larvae. D-F). Quantification of total (D) and species-specific (E and F) PCs in whole larvae (D and F) and dissected CNS (D, E, and F) of wildtype and <italic>ifc<sup>-/-</sup></italic>larvae. G-I) Quantification of total (G) and species-specific (H and I) PEs in whole larvae (G and H) and dissected CNS (G, H, and I) of wild-type and <italic>ifc<sup>-/-</sup></italic> larvae. J-L) Quantification of total (J) and species-specific (K and L) PSs in the whole larvae (J and L) and dissected CNS (J, K, and L) of wild-type and <italic>ifc<sup>-/-</sup></italic> larvae. Statistics: * denotes <italic>p</italic> &lt; 0.05, ** denotes <italic>p</italic> &lt; 0.01, *** denotes <italic>p</italic> &lt; 0.001, **** denotes <italic>p</italic> &lt; 0.0001, and ns, not significant.</p></caption>
<graphic xlink:href="573836v4_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2h">
<title>Reduction of dihydroceramide synthesis suppresses the <italic>ifc</italic> CNS phenotype</title>
<p>Following its synthesis, ceramide is transported by CERT from the ER to the Golgi, but CERT is less efficient at transporting dihydroceramide than ceramide.<sup><xref ref-type="bibr" rid="c13">13</xref></sup> The expanded nature of the ER in <italic>ifc</italic> mutant larvae supports a model in which loss of <italic>ifc</italic> triggers excessive accumulation and retention of dihydroceramide in the ER due to CERT’s inefficiency of transporting dihydroceramide to the Golgi, driving ER expansion and glial swelling. If this model is correct, reduction of dihydroceramide levels should suppress the <italic>ifc</italic> CNS phenotype. In agreement with this model, we found that the <italic>schlank<sup>G0365</sup></italic> loss of function allele dominantly suppressed the enhanced RFP expression (<xref rid="fig7" ref-type="fig">Figure 7M</xref>) and CNS elongation phenotypes of <italic>ifc</italic> (<xref rid="fig7" ref-type="fig">Figure 7N</xref>). We also found that glial-specific depletion of <italic>schlank</italic> suppressed the internal membrane accumulation (<xref rid="fig7" ref-type="fig">Figures 7A-B</xref>), reduced lipid droplet size (<xref rid="fig7" ref-type="fig">Figures 7C-D</xref>, and <xref rid="fig7" ref-type="fig">7O</xref>), glial swelling (<xref rid="fig7" ref-type="fig">Figures 7E-F</xref>, and <xref rid="figs12" ref-type="fig">S12</xref>), enhanced RFP expression (<xref rid="fig7" ref-type="fig">Figure 7M</xref>), CNS elongation (<xref rid="fig7" ref-type="fig">Figure 7N</xref>), and reduced optic lobe (<xref rid="figs5" ref-type="fig">Figure S5</xref>) phenotypes observed in otherwise <italic>ifc</italic> mutant larvae. Our data support the model that inappropriate retention of dihydroceramide in the ER drives ER expansion and glial swelling and dysfunction.</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Figure 7.</label>
<caption><title>Glial-specific knockdown of <italic>ifc</italic> triggers neuronal cell death.</title> <p>A-D) TEM images of cortex glia cell body (A and B) and neuronal cell bodies (C and D) at low (A) and high (B, C, and D) magnifications in the nerve cord of <italic>ifc<sup>-/-</sup></italic>; <italic>repo&gt;schlank RNAi</italic> late third instar larvae. Dotted lines demarcate cell boundary of cortex glia; yellow squares highlight regions magnified in A. Scale bar: 3μm for A, 1μm for B, and 2μm for C and D. (B) Cy denotes cytoplasm; Nu denotes nucleus. (C-D) Black asterisk denotes lipid droplets. E-F) Ventral views of abdominal sections of CNS of <italic>ifc<sup>-/-</sup></italic>; <italic>UAS-schlank RNAi/+</italic> larvae (E) and <italic>ifc<sup>-/-</sup></italic>; repoGAL4/<italic>UAS-schlank RNAi</italic> larvae (F) labeled for neurons (ELAV, Green) and cortex glia (FABP, magenta/grey). Scale bar is 30μm for E-F. G-L) Low (G-L) and high (G’-L’ and G’’-L’’) magnification views of the brain (G-I) and nerve cord (J-L) of late-third instar larvae of the indicated genotypes labeled for ELAV (magenta or greyscale) and Caspase-3 (green). Arrows indicate regions of high Caspase-3 signal and/or apparent neuronal cell death identified by perforations in the neuronal cell layer. Scale bar is 50μm for panels G-L and 10μm for panels G’-L’’. M-N) Quantification of CNS elongation (M) and 3xP3 RFP intensity (N) in <italic>ifc</italic> mutants alone, <italic>ifc</italic> mutants with one copy of <italic>schlank[G0365]</italic> loss-of-function allele, or <italic>ifc</italic> mutants in which <italic>schlank</italic> function is reduced via RNAi in glial cells. O) Quantification of the area of lipid droplets in dissected CNS of <italic>ifc</italic> mutants and <italic>ifc</italic> mutants in which <italic>schlank</italic> function is reduced via RNAi in glial cells. Anterior is up in all panels. P-Q) Quantification of Cleaved Caspase-3 neurons for panels G-I (P) and J-L (Q). Statistics: * denotes <italic>p</italic> &lt; 0.05, ** denotes <italic>p</italic> &lt; 0.01, *** denotes <italic>p</italic> &lt; 0.001, **** denotes <italic>p</italic> &lt; 0.0001, and ns, not significant.</p></caption>
<graphic xlink:href="573836v4_fig7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2i">
<title>Glial-specific depletion of <italic>ifc</italic> function triggers neuronal cell death</title>
<p>Loss of <italic>DEGS1/ifc</italic> in human and flies has been shown to promote neurodegeneration and neuronal cell death,<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c17">17</xref></sup> but whether neuronal death results from an intrinsic defect in neurons or is induced by glial dysfunction remains unclear. By using Cleaved caspase-3 as a marker of dying cells<sup><xref ref-type="bibr" rid="c54">54</xref>,<xref ref-type="bibr" rid="c55">55</xref></sup> and ELAV to track neurons, we tracked neuronal cell death in the brain and ventral nerve cord of wild-type and <italic>ifc<sup>-/-</sup></italic>mutant late-third instar larvae. In wildtype, little to no cell death was evident in the brain or nerve cord and neurons appear smoothly packed next to each other; in contrast, in <italic>ifc<sup>-/-</sup></italic> larvae, significant cell death was apparent in the brain and to a lesser degree in the nerve cord, with Caspase-3 staining often highlighting small perforations in the neuronal cell layer (<xref rid="fig7" ref-type="fig">Figures 7G-H, 7P</xref>, and <xref rid="figs7" ref-type="fig">S7</xref>). This perforated pattern was associated with and more expansive than Caspase-3 staining, indicating the perforations mark Caspase-positive dying neurons and Caspase-negative dead neurons. Glial-specific depletion of <italic>schlank</italic> function in otherwise <italic>ifc<sup>-/-</sup></italic> larvae suppressed the neuronal cell death phenotype (<xref rid="fig7" ref-type="fig">Figures 7I</xref> and <xref rid="fig7" ref-type="fig">7P</xref>), supporting the model that loss of <italic>ifc</italic> function specifically in glia, rather than a specific requirement for <italic>ifc</italic> function in neurons, drives neuronal cell death. To directly test whether <italic>ifc</italic> function in glia is required to guard against neuronal cell death, we used the GAL4-UAS system and RNAi mediated gene interference to deplete <italic>ifc</italic> function specifically in glia (<italic>repo-GAL4</italic>) or in neurons (<italic>elav-GAL4; repo-GAL80</italic>) and found that glial-specific, but not neuronal-specific, depletion of <italic>ifc</italic> function drove significant neuronal cell death in the brain and to a greater extent the nerve cord, a phenotype that was enhanced upon removal of one copy of <italic>ifc</italic> (<xref rid="fig7" ref-type="fig">Figures 7J-L, 7Q</xref>, and <xref rid="figs13" ref-type="fig">S13</xref>). Loss of <italic>ifc</italic> function then triggers glial dysfunction, which in turn drives neuronal cell death.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Our work on <italic>ifc</italic> supports a model in which loss of <italic>ifc/DEGS1</italic> function drives glial dysfunction through the accumulation and inappropriate retention of dihydroceramide in the ER of glia with this proximal defect driving ER expansion, glial swelling, and subsequent neuronal cell death and neurodegeneration. A large increase in dihydroceramide would also impact ER membrane structure: ER membranes are typically loosely packed, thin, semi-fluid structures, with sphingolipids comprising just 3% of ER phospholipids.<sup><xref ref-type="bibr" rid="c47">47</xref></sup> Sphingolipids in general and dihydroceramide in specific are highly saturated lipids, promote lipid order, tighter lipid packing, membrane rigidity, and thicker membranes.<sup><xref ref-type="bibr" rid="c56">56</xref>,<xref ref-type="bibr" rid="c57">57</xref></sup> Our observation of thick ER membranes in cortex glia in <italic>ifc</italic><sup>-/-</sup> larvae (<xref rid="fig5" ref-type="fig">Figure 5</xref>) aligns with increased dihydroceramide levels in the ER. In this context, we note that of many clinical observations made on an HLD-18 patient, one was widening of the ER in Schwann cells,<sup><xref ref-type="bibr" rid="c8">8</xref></sup> a finding that when combined with our work suggests that dihydroceramide accumulation in the ER is the proximal cause of HLD-18.</p>
<p>Although ER expansion represents the most proximal effect of loss of <italic>ifc/DEGS1</italic> function and dihydroceramide accumulation on cortex glia, other organelles and their functions are likely also disrupted, minimally as a consequence of ER disruption. For example, the apparent reduction of the lysosome marker, LAMP, in cortex glia of <italic>ifc</italic> mutant larvae correlates with increased RFP levels and the presence of bright RFP puncta or aggregates in this cell type, suggesting impaired lysosome function contributes to increased RFP perdurance and aggregation. Defects in the activity of multiple organelles may collaborate to elicit the full phenotype manifested by loss of <italic>ifc/DEGS1</italic> function, resulting in glial dysfunction and subsequent neuronal cell death.</p>
<p>Increased dihydroceramide levels may contribute to a broader spectrum of neurodegenerative diseases than simply HLD-18. Recent work reveals that gain of function mutations in <italic>SPTLC1</italic> and <italic>SPTLC2</italic>, which encode components of the SPT complex that catalyzes the initial, rate limiting step of <italic>de novo</italic> ceramide and sphingolipid biosynthesis,<sup><xref ref-type="bibr" rid="c55">55</xref></sup> cause juvenile ALS via increased sphingolipid biosynthesis.<sup><xref ref-type="bibr" rid="c18">18</xref>–<xref ref-type="bibr" rid="c22">22</xref></sup> Of all sphingolipids, the relative levels of dihydroceramide were increased the most in patient plasma samples, suggesting that DEGS1 activity becomes limiting in the presence of enhanced SPT activity and that dihydroceramide accumulation contributes to juvenile ALS. Any mutations that increase metabolite flux through the ceramide pathway upstream of DEGS1 may then increase dihydroceramide levels, drive ER expansion and cell swelling, and lead to neurodegeneration, with disease severity predicated on the extent of excessive dihydroceramide accumulation. Model systems, like flies, can harness the power of genetic modifier screens to identify genes and pathways (potential therapeutic targets), that can be tweaked to ameliorate the effect of elevated dihydroceramide levels on neurodegeneration.</p>
<p>Our work appears to pinpoint glia as the cell type impacted by loss of <italic>ifc/DEGS1</italic> function, specifically glia that exhibit great demand for membrane biogenesis like cortex glia in the fly and oligodendrocytes or Schwann cells in mammals. In larvae, <italic>ifc</italic> is expressed at higher levels in glial cells than in neurons, and its genetic function is required at a greater level in glia than neurons to govern CNS development. Our unpublished work on other genes in the ceramide metabolic pathway reveals similar glial-centric expression patterns in the larval CNS to that observed for <italic>ifc</italic>, suggesting they too function primarily in glia rather than neurons at this stage. In support of this model, a study on CPES, which converts ceramide into CPE, the fly analog of sphingomyelin, revealed that CPES is required in cortex glia to promote their morphology and homeostasis and to protect flies from photosensitive epilepsy.<sup><xref ref-type="bibr" rid="c59">59</xref></sup> Similarly, ORMDL, a dedicated negative regulator of the SPT complex, is required in oligodendrocytes to maintain proper myelination in mice.<sup><xref ref-type="bibr" rid="c60">60</xref></sup> Given that many glial cell types are enriched in sphingolipids and exhibit a great demand for new membrane biogenesis during phases of rapid neurogenesis and axonogenesis, we believe that glial cells, such as cortex glia, oligodendrocytes, and Schwann cells, rather than neurons manifest a greater need for <italic>ifc/DEGS1</italic> function and ceramide synthesis during developmental stages marked by significant nervous system growth.</p>
<p>Will this glial-centric model for <italic>ifc/DEGS1</italic> function, and more generally ceramide synthesis, hold true in the adult when neurogenesis is largely complete and the demand for new membrane synthesis in glia dissipates? Recent work in the adult fly eye suggests it may not. Wang et al.<sup><xref ref-type="bibr" rid="c61">61</xref></sup> argued that the GlcT enzyme, which converts ceramide to glucosylceramide, is expressed at much higher levels in neurons than glia, and that glucosylceramide is then transported from neurons to glial cells for its degradation, suggesting cell-type specific compartmentalization of sphingolipid synthesis in neurons and its degradation in glia in the adult. In the future, it will be exciting to uncover whether genes of the sphingolipid metabolic pathway alter their cell-type specific requirements as a function of developmental stage.</p>
<p>We note that cortex glia are the major phagocytic cell of the CNS and phagocytose neurons targeted for apoptosis as part of the normal developmental process.<sup><xref ref-type="bibr" rid="c23">23</xref>–<xref ref-type="bibr" rid="c26">26</xref></sup> Thus, while we favor the model that <italic>ifc</italic> triggers neuronal cell death due to glial dysfunction, it is also possible that increased detection of dying neurons arises due at least in part to a decreased ability of cortex glia to clear dying neurons from the CNS. At present, the large number of neurons that undergo developmentally programmed cell death combined with the significant disruption to brain and ventral nerve cord morphology caused by loss of <italic>ifc</italic> function render this question difficult to address. Additional evidence does, however, support the idea that loss of <italic>ifc</italic> function drives excess neuronal cell death: Clonal analysis in the fly eye reveals that loss of <italic>ifc</italic> drives photoreceptor neuron degeneration<sup><xref ref-type="bibr" rid="c17">17</xref></sup>, indicating that loss of <italic>ifc</italic> function drives neuronal cell death; cortex-glia specific depletion of <italic>CPES</italic>, which acts downstream of <italic>ifc</italic>, disrupts neuronal function and induces photosensitive epilepsy in flies<sup><xref ref-type="bibr" rid="c59">59</xref></sup>, indicating that genes in the ceramide pathway can act non-autonomously in glia to regulate neuronal function; recent genetic studies reveal that other glial cells can compensate for impaired cortex glial cell function by phagocytosing dying neurons<sup><xref ref-type="bibr" rid="c62">62</xref></sup>, and we observe that the cell membranes of subperineurial glia enwrap dying neurons in <italic>ifc</italic> mutant larvae (Fig. S14), consistent with similar compensation occurring in this background, and in humans, loss of function mutations in <italic>DEGS1</italic> cause neurodegeneration.<sup><xref ref-type="bibr" rid="c7">7</xref>–<xref ref-type="bibr" rid="c9">9</xref></sup> Clearly, future work is required to address this question for <italic>ifc/DEGS1</italic> and perhaps other members of the ceramide biogenesis pathway.</p>
<p>Altered glial function may not only derive from dihydroceramide buildup in the ER, but also from altered cell membrane structure due to the replacement of ceramide and its derivates, such as GlcCer and CPE, with the cognate forms of dihydroceramide. Relative to dihydroceramide species, the 4-5 <italic>trans</italic> carbon-carbon double bond in the sphingoid backbone of ceramide-containing sphingolipids enables them to form more stable hydrogen bonds with water molecules and facilitates their ability to associate with lipids of different saturation levels.<sup><xref ref-type="bibr" rid="c5">5</xref></sup> A high dihydroceramide to ceramide ratio has been shown to form rigid gel-like domains within model membranes and to destabilize biological membranes by promoting their permeabilization.<sup><xref ref-type="bibr" rid="c63">63</xref>,<xref ref-type="bibr" rid="c64">64</xref></sup> As even minor alterations to membrane properties can disrupt glial morphology,<sup><xref ref-type="bibr" rid="c65">65</xref></sup> such alterations in membrane rigidity and stability may underlie the failure of cortex glia to enwrap adjacent neurons. The observed increase in saturation of PE, PC, and PS in the CNS of <italic>ifc</italic> mutant larvae may reflect a compensatory response employed by cells to stabilize cell membranes and guard cell integrity when challenged with elevated levels of dihydroceramide.</p>
<p>The expansion of ER membranes coupled with loss of lipid droplets in <italic>ifc</italic> mutant larvae suggests that the apparent demand for increased membrane phospholipid synthesis may drive lipid droplet depletion, as lipid droplet catabolism can release free fatty acids to serve as substrates for lipid synthesis. At some point, the depletion of lipid droplets, and perhaps free fatty acids as well, would be expected to exhaust the ability of cortex glia to produce additional membrane phospholipids required for fully enwrapping neuronal cell bodies. Under wild-type conditions, many lipid droplets are present in cortex glia during the rapid phase of neurogenesis that occurs in larvae. During this phase, lipid droplets likely support the ability of cortex glia to generate large quantities of membrane lipids to drive membrane growth needed to ensheath newly born neurons. Supporting this idea, lipid droplets disappear in the adult <italic>Drosophila</italic> CNS when neurogenesis is complete and cortex glia remodeling stops.<sup><xref ref-type="bibr" rid="c30">30</xref></sup> We speculate that lipid droplet loss in <italic>ifc</italic> mutant larvae contributes to the inability of cortex glia to enwrap neuronal cell bodies. Prior work on lipid droplets in flies has focused on stress-induced lipid droplets generated in glia and their protective or deleterious roles in the nervous system.<sup><xref ref-type="bibr" rid="c66">66</xref>–<xref ref-type="bibr" rid="c68">68</xref></sup> Work in mice and humans has found that more lipid droplets are often associated with the pathogenesis of neurodegenerative diseases,<sup><xref ref-type="bibr" rid="c69">69</xref>–<xref ref-type="bibr" rid="c71">71</xref></sup> but our work correlates lipid droplet loss with CNS defects. In the future, it will be important to determine how lipid droplets impact nervous system development and disease.</p>
</sec>
<sec id="s7">
<title>Methods</title>
<sec id="s7a">
<title>Key resources table</title>
<sec id="s7a1">
<title>Fly stocks used</title>
<table-wrap id="utbl1" orientation="portrait" position="float">
<graphic xlink:href="573836v4_utbl1.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="573836v4_utbl1a.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="573836v4_utbl1b.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s7a2">
<title>Antibodies and lipid marker used</title>
<table-wrap id="utbl2" orientation="portrait" position="float">
<graphic xlink:href="573836v4_utbl2.tif" mimetype="image" mime-subtype="tiff"/>
<graphic xlink:href="573836v4_utbl2a.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s7a3">
<title>Deposited data</title>
<table-wrap id="utbl3" orientation="portrait" position="float">
<graphic xlink:href="573836v4_utbl3.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<sec id="s7a4">
<title>Software used</title>
<table-wrap id="utbl4" orientation="portrait" position="float">
<graphic xlink:href="573836v4_utbl4.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
</sec>
<sec id="s8">
<title>Method details</title>
<sec id="s8a">
<title>Fly husbandry</title>
<p>Flies were raised on standard molasses-based food at 25°C. Unless otherwise noted, wild type is an otherwise wild-type stock harboring the <italic>M{3xP3-RFP.attP}ZH-51D</italic> insert in an isogenic second chromosome.</p>
</sec>
<sec id="s8b">
<title>Mutagenesis</title>
<p>A standard autosomal recessive forward genetic screen was carried out using 25-30 μm EMS to mutagenize a <italic>M{3xP3-RFP.attP}ZH-51D</italic> isogenic second chromosome. Homozygous mutant third instar larvae were visually screened under a standard fluorescent microscope for defects in CNS morphology. A detailed description of the screen and all other identified genes will be described elsewhere.</p>
</sec>
<sec id="s8c">
<title>Creation of recombinant lines and identification of second site mutations in <italic>ifc-KO</italic> <bold>chromosome</bold></title>
<p>Standard genetic methods were used to generate fly strains that contained specific combinations of GAL4 and UAS-linked transgenes in the <italic>ifc<sup>js3</sup></italic>or <italic>ifc-KO</italic> background. During this process, we uncovered that the <italic>ifc-KO</italic> deletion could be unlinked from at least one second chromosomal mutation that caused early larval lethality, resulting in homozygous <italic>ifc-KO</italic> flies that survived to late L3 to early pupa. A subsequent EMS-based F2 lethal non-complementation screen using the <italic>M{3xP3-RFP.attP}ZH-51D</italic> isogenic second chromosome as target chromosome and screening against the <italic>ifc-KO</italic> chromosome identified multiple mutations in four complementation groups that led to an early larval lethal phenotype. Whole genome sequencing identified these genes as <italic>Med15</italic>, <italic>lwr</italic>, <italic>Nle</italic>, and <italic>Sf3b1</italic>; all four genes reside within ∼90 Kb of each other in chromosomal bands 21D1-21E2 near the telomere in chromosome 2L, identifying the site of the associated lethal mutations and suggesting the actual lesion may be a small deletion that removes these genes. The following alleles of these genes are available at Bloomington Stock Center: <italic>Med15<sup>js1</sup></italic>(Q175*), <italic>Med15<sup>js2</sup></italic> (Q398*), <italic>Med15<sup>js3</sup></italic> (C655Y), <italic>lwr<sup>js1</sup></italic> (I4N), <italic>lwr<sup>js2</sup></italic>(E12K), <italic>Nle<sup>js1</sup></italic>(W146R), <italic>Nle<sup>js2</sup></italic> (L125P), <italic>Nle<sup>js3</sup></italic> (Q242*), <italic>Sf3b1<sup>js1</sup></italic> (R1160*), <italic>Sf3b1<sup>js</sup></italic><sup><xref ref-type="bibr" rid="c2">2</xref></sup> (Q1264*), <italic>Sf3b1<sup>js3</sup></italic> (570 bp deletion at the following coordinates chr2L571720-572290; this deletion removes amino acids 1031 through 1222 and introduces a frameshift into the reading frame).</p>
</sec>
<sec id="s8d">
<title>Gene rescue and in vivo RNAi phenocopy assays</title>
<p>To restrict UAS-linked transgene expression specifically to glia, we used the <italic>repoGAL4</italic> driver line. To restrict UAS-linked transgene expression specifically to neurons, we paired the <italic>elavGAL4</italic> driver lines, which activates transgene expression strongly in all neurons and moderately in glia, with <italic>repoGAL80</italic>, which blocks GAL4-dependent activation in glia. We used <italic>P{VSH330794}</italic> (VDRC 330794) for the RNAi experiments and <italic>UAS-ifc</italic><sup><xref ref-type="bibr" rid="c68">68</xref></sup> and <italic>UAS-DEGS1</italic> (BDSC 79200) for the gene rescue assays. All gene rescue experiments were performed in the <italic>ifc<sup>js3</sup></italic>/<italic>ifc-KO</italic> background with the UAS-transgene placed into the <italic>ifc<sup>js3</sup></italic> background and the GAL4 drivers into the <italic>ifc-KO</italic> background.</p>
<p>The GAL4-UAS method was also used to assess the phenotype of each glial subtype. In combination with the <italic>UAS-Myr-GFP</italic> transgene, which labels cell membranes, we used the following GAL4 lines to trace the morphology of each glial subtype in wild type and <italic>ifc<sup>-/-</sup></italic> larvae: <italic>GMR85G01-GAL4</italic> (perineurial glia; BDSC 40436), <italic>GMR54C07-GAL4</italic> (subperineurial glia; BDSC 50472), <italic>GMR54H02-GAL4</italic> (cortex glia; BDSC 45784), <italic>GMR56F03-GAL4</italic> (ensheathing glia; BDSC 77469 and 39157), and <italic>GMR86E01-GAL4</italic> (astrocyte-like glia; BDSC45914). The <italic>UAS-Myr-GFP</italic> transgene was placed into the <italic>ifc<sup>js3</sup></italic>background; each glial GAL4 line was placed into the <italic>ifc-KO</italic> background.</p>
<p>The GAL4-UAS method was used to assess the ability of <italic>UAS-ifc</italic> and <italic>UAS-DEGS1</italic> transgenes to rescue the lethality of otherwise <italic>ifc</italic> mutant larvae. <italic>ifc-KO/CyO Tb; repo-GAL4/TM6B Tb</italic> males were crossed to each of the following lines: <italic>ifc<sup>js3</sup>/CyO Tb; UAS-ifc</italic>; <italic>ifc<sup>js3</sup>/CyO Tb; UAS-DEGS1</italic>; <italic>ifc<sup>js3</sup>/CyO Tb.</italic> All adult flies were sorted into Curly and non-Curly and then counted; all non-Curly flies lacked the <italic>TM6B Tb</italic> balancer indicating they carried <italic>repo-GAL4</italic> and thus were likely rescued to viability by glial expression of <italic>ifc</italic> or <italic>DEGS1</italic>. Standard Mendelian ratios were then used to predict the expected number of <italic>ifc</italic> mutant flies if all survived to adulthood. The total number of observed adult <italic>ifc</italic> mutant flies, identified by lack of Curly wings, was then divided by this number to obtain the percentage of <italic>ifc</italic> mutant flies that survived to adulthood. 2452 total flies were assayed for the <italic>UAS-ifc</italic> cross, 1303 for the <italic>UAS-DEGS1</italic> cross, and 1030 for the control cross.</p>
</sec>
<sec id="s8e">
<title>DNA sequencing</title>
<p>Genomic DNA was obtained from wild type larvae or larvae homozygous for each relevant mutant line and provided to GTAC (Washington University) or GENEWIZ for next-generation or Sanger sequencing.</p>
</sec>
<sec id="s8f">
<title>RNA in-situ hybridization</title>
<p><italic>ifc</italic> RNA probes for in-situ hybridization chain reaction (HCR) were designed and made by Molecular Instruments (HCR™ RNA-FISH v3.0).<sup><xref ref-type="bibr" rid="c73">73</xref></sup> Wild type CNS was harvested and fixed in 2% paraformaldehyde at late L3. The fixed CNS underwent gradual dehydration and rehydration, followed by standard hybridization and amplification steps of the HCR protocol.<sup><xref ref-type="bibr" rid="c73">73</xref></sup> For double labeling with antibody, the post-HCR labeled CNS was briefly fixed for 30 minutes prior to standard antibody labeling protocol to identify specific CNS cell type(s) with highly localized <italic>ifc</italic> <sub>RNAs.74,75</sub></p>
</sec>
<sec id="s8g">
<title>MultiColor FlpOut labeling of glial subtypes</title>
<p>For glial labeling in the control background, the <italic>MCFO1</italic> line was crossed to <italic>GMR-GAL4</italic> driver lines for each glial subtype (Supplemental Table 1).<sup><xref ref-type="bibr" rid="c33">33</xref></sup> For glial labeling in <italic>ifc<sup>-/-</sup></italic> background, the <italic>MCFO1</italic> line was placed in the <italic>ifc<sup>JS3</sup></italic> background, each of the five glial-specific GMR-GAL4 lines were placed individually into the <italic>ifc-KO</italic> background, and then the MCFO, <italic>ifc<sup>JS3</sup></italic> line was crossed to each glial specific GAL4, <italic>ifc-KO</italic> line. Flies were allowed to lay eggs for 24 hr at 25°C, and progeny were raised at 25°C for 4 days prior to heat-activated labeling. On day 4 after egg-laying, F1 larvae were incubated in a 37°C water bath for 5-minutes. When wild-type or <italic>ifc<sup>-/-</sup></italic> mutant larvae reached late L3, which was day 5-6 for control and day 9-10 for <italic>ifc<sup>-/-</sup></italic> mutants, the CNS was dissected, fixed, stained, and then analyzed under a Zeiss LSM 700 Confocal Microscope for the presence of clones, using Zen software.</p>
</sec>
<sec id="s8h">
<title>Antibody generation</title>
<p>YenZym (CA, USA) was used as a commercial source to generate affinity purified antibodies against a synthetic peptide that corresponded to amino acids 85-100 (TLDGNKLTQEQKGDKP) of FABP isoform B. Briefly, the peptide was conjugated to KLH, used as an immunogen in rabbits to generate a peptide-specific antibody response, and antibodies specific to the peptide were affinity purified. The affinity-purified antibodies were confirmed to label cortex glia specifically based on comparison of antibody staining relative to Myr-GFP when a UAS-Myr-GFP was driven under control of the cortex specific glial GAL4 driver GMR-54H02 (<xref rid="figs3" ref-type="fig">Figure S3</xref>). The FABP antibodies are used at 1:500-1:1000.</p>
</sec>
<sec id="s8i">
<title>Immunofluorescence and lipid droplet staining</title>
<p>Gene expression analysis was performed essentially as described in Patel.<sup><xref ref-type="bibr" rid="c76">76</xref></sup> Briefly, the larval CNS was dissected in PBS, fixed in 2.5% paraformaldehyde for 55 minutes, and washed in PTx (1xPBS, 0.1% TritonX-100. The fixed CNS was incubated in primary antibody with gentle rocking overnight at 4°C. Secondary antibody staining was conducted for at least two hours to overnight at room temperature. All samples were washed in PTx at least five times and rocked for an hour before and after secondary antibody staining. A detailed list of the primary and secondary antibodies is available in Supplemental Table 2. Dissected CNS were mounted either in PTx or dehydrated through an ethanol series and cleared in xylenes prior to mounting in DPX mountant.<sup><xref ref-type="bibr" rid="c77">77</xref></sup> All imaging was performed on a Zeiss LSM-700 Confocal Microscope, using Zen software.</p>
<p>For lipid droplet staining, the fixed CNS was incubated for 30 minutes at room temperature at 1:200 dilution of 1mg/mL BODIPY™ 493/503 (Invitrogen: D3922). It was then rinsed thoroughly in PBS and immediately mounted for imaging on a Zeiss LSM-700 Confocal Microscope, using Zen software.</p>
</sec>
<sec id="s8j">
<title>Transmission electron microscopy (TEM) imaging</title>
<p>For transmission electron microscopy (TEM), samples were immersion fixed overnight at 4°C in a solution containing 2% paraformaldehyde and 2.5% glutaraldehyde in 0.15 M cacodylate buffer with 2 mM CaCl2, pH 7.4. Samples were then rinsed in cacodylate buffer 3 times for 10 minutes each and subjected to a secondary fixation for one hour in 2% osmium tetroxide/1.5% potassium ferrocyanide in cacodylate buffer. Following this, samples were rinsed in ultrapure water 3 times for 10 minutes each and stained overnight in an aqueous solution of 1% uranyl acetate at 4°C. After staining was complete, samples were washed in ultrapure water 3 times for 10 minutes each, dehydrated in a graded acetone series (50%, 70%, 90%, 100% x4) for 15 minutes in each step, and infiltrated with microwave assistance (Pelco BioWave Pro, Redding, CA) into Spurr’s resin. Samples were then cured in an oven at 60°C for 72 hours and post-curing, 70 nm thin sections were cut from the resin block, post-stained with uranyl acetate and Sato’s lead and imaged on a Transmission Electron Microscope (JEOL JEM-1400 Plus, Tokyo, Japan) operating at 120 KeV.</p>
</sec>
<sec id="s8k">
<title>Lipidomics</title>
<p>Untargeted lipidomics analysis was conducted on whole larva and dissected CNS of wild type and <italic>ifc<sup>-/-</sup></italic> mutants at the late-third instar stage. Five replicates were prepared for each set of experiments. For whole larvae, at least 15 larvae of each genotype were used for each replicate. For the dissected CNS, at least 50 wild type and 60 <italic>ifc</italic><sup>-/-</sup> CNS were used per replicate. Immediately following collection or dissection, larvae and the dissected CNS were flash frozen in liquid nitrogen and placed at −80°C.</p>
<p>Lipids were extracted from frozen whole larvae and dissected larval CNS samples by using an Omni Bead Ruptor Elite Homogenizer using acetonitrile:methanol:water (2:2:1; 40 μL/mg tissue). Two Ultrahigh performance LC-(UHPLC)/MS systems were used in this work: a Thermo Vanquish Flex UHPLC system with a Thermo Scientific Orbitrap ID-X and an Agilent 1290 Infinity II UPLC system with an Agilent 6545 QTOF as described previously.<sup><xref ref-type="bibr" rid="c78">78</xref></sup> Lipids were separated on a Waters Acquity HSS T3 column (150 x 2.1 mm, 1.8 mm). The mobile-phase solvents were composed of A: 0.1% formic acid, 10 mM ammonium formate, 2.5 μM medronic acid in 60:40 acetonitrile:water; and B = 0.1% formic acid, 10 mM ammonium formate in 90:10 2-propanol:acetonitrile. The column compartment was maintained at 60 °C. The following linear gradient was applied at a flow rate of 0.25 mL min-1: 0 – 2 min, 30% B; 17 min, 75% B; 20 min, 85% B; 23 – 26 min, 100% B. The injection volume 4 μL for all lipids analysis. Data was acquired in positive ion.</p>
<p>LC/MS data were processed and analyzed with the open-source Skyline software.<sup><xref ref-type="bibr" rid="c79">79</xref></sup> Lipid MS/MS data were annotated with Agilent Lipid Annotator software.</p>
</sec>
<sec id="s8l">
<title>RNA sequencing and analysis</title>
<p>To determine the CNS-specific transcriptional changes upon loss of <italic>ifc</italic>, RNA-seq was conducted on five replicates of dissected CNS tissue derived from wild type and <italic>ifc<sup>-/-</sup></italic> mutant late-third instar larvae. For each replicate, roughly 30-35 dissected CNS of wild type or <italic>ifc-/-</italic> larvae were used. Invitrogen™ RNAqueous™-Micro Total RNA Isolation Kit (AM1931) was used to extract RNA. Agilent 4200 TapeStation system was used for RNA quality control.</p>
<p>Samples were prepared according to library kit manufacturer’s protocol, indexed, pooled, and sequenced on an Illumina NovoSeq. Basecalls and demultiplexing were performed with Illumina’s bcl2fastq software and a custom python demultiplexing program with a maximum of one mismatch in the indexing read. RNA-seq reads were then aligned to the Ensembl release 76 primary assembly with STAR version 2.5.1a.<sup><xref ref-type="bibr" rid="c80">80</xref></sup> Gene counts were derived from the number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.6-p5.<sup><xref ref-type="bibr" rid="c81">81</xref></sup> Isoform expression of known Ensembl transcripts were estimated with Salmon version 0.8.2.<sup><xref ref-type="bibr" rid="c82">82</xref></sup> To find the most critical genes, the raw counts were variance stabilized with the R/Bioconductor package DESeq2<sup><xref ref-type="bibr" rid="c83">83</xref></sup> and was then analyzed via weighted gene correlation network analysis with the R/Bioconductor package WGCNA.<sup><xref ref-type="bibr" rid="c84">84</xref></sup></p>
</sec>
<sec id="s8m">
<title>Statistics</title>
<p>All data are presented as mean ± SEM. Statistical significance between groups was determined using Student’s <italic>t</italic>-test or one-way ANOVA with multiple comparisons, and with varying levels of significance assessed as * <italic>P</italic> &lt; 0.05, ** <italic>P</italic> &lt; 0.01, *** <italic>P</italic> &lt; 0.001, **** <italic>P</italic> &lt; 0.0001, and ns, not significant.</p>
</sec>
</sec>
</sec>
</body>
<back>
<sec id="d1e6305">
<title>Supplemental figures and information</title>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1.</label>
<caption><title>Ceramide metabolic changes in whole larvae.</title> <p>A) Normalized quantification of the relative levels of dihydroceramide, ceramide, and six related sphingolipid species in the whole larvae of wild-type and <italic>ifc<sup>-/-</sup></italic> late-third instar larvae. B) Chemical structure of dihydroceramide phosphoethanolamine (DiCPE), ceramide phosphoethanolamine (CPE), glucosyl-dihydroceramide (Glc-DiCer), glucosyl-ceramide (GlcCer), sphinganine, and sphingosine; arrow indicates the cis carbon-carbon double bond between C4 and C5 in the sphingoid backbone created by the enzymatic action of Ifc/DEGS1.</p></caption>
<graphic xlink:href="573836v4_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2.</label>
<caption><title>The <italic>M{3xP3-RFP.attP}ZH-51D</italic> transgene insert labels most glia.</title> <p>Low and high magnification images of late third instar larvae that harbor the <italic>M{3xP3-RFP.attP}ZH-51D</italic> transgene showing RFP expression and markers for different glial subtypes. <bold>A) Cortex glia</bold>: Ventral view of full CNS labeled for FABP to label cortex glia and RFP. Inset shows high magnification view of the brain with clear overlap of FABP and RFP expression (arrows).</p><p>B) <bold>Astrocyte-like glia</bold>: Dorsal view of thoracic and abdominal region of CNS labeled for Ebony to label astrocyte glia and RFP; arrows highlight overlap of RFP and Ebony expression in some astrocyte-like glia. <bold>C) Ensheathing glia</bold>: Dorsal view of thoracic and abdominal region of CNS labeled for RFP and Myr-GFP. The <italic>UAS-Myr-GFP</italic> transgene is driven by the ensheathing glia-specific GAL4 driver line <italic>GMR56F03</italic>. Note the colocalization of RFP and GFP in the nerves exiting the CNS and the circular structures of ensheathing glia near the dorsal midline. <bold>D) Subperineurial glia</bold>: The two left-most panels show ventral views of thoracic and abdominal region of CNS labeled for RFP and Myr-GFP driven by the <italic>GMR54C07-GAL4</italic> line, which is specific to subperineurial glia. Arrows identify nuclei of subperineurial glia, which contain RFP and are encircled by Myr-GFP. Right panel shows cross section of CNS that highlights RFP and Myr-GFP co-expression in subperineurial glia at lateral edge of CNS (arrows). <bold>E) Perineurial glia</bold>: Ventral view of brain labeled for RFP and Myr-GFP driven by the <italic>GMR85G01-GAL4</italic> line, which is thought to be specific for perineurial glia. Arrows point to the small GFP-expressing perineurial glia, most of which do not express detectable levels of RFP. Visual inspection and quantification of the relative expression of RFP to each glial subtype marker in at least five brain-nerve cord complexes revealed that essentially all cortex, astrocyte, ensheathing, and subperineurial glia expressed RFP, but that astrocyte-like glia expressed RFP at much lower levels than the other three glial subtypes, and that most perineurial glia did not express RFP.</p></caption>
<graphic xlink:href="573836v4_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3.</label>
<caption><title>Most 3xP3-GFP or 3xP3-RFP transgenes label glia.</title> <p>Low magnification views of the indicated 3xP3 transgenes driving GFP (left) or RFP (right) in the CNS. Low magnification views illustrate that the three 3xP3 transgenes label or highlight the CNS. High magnification views illustrate that all three transgenes label cortex glia (arrowheads), which are marked by FABP. Two of the three transgenes strongly label astrocyte-like glia (arrowheads), which are marked by Ebony. Two of the three transgenes also clearly label ensheathing glia (arrows). Scale bar is 100 microns for low magnification images; 50 microns for high magnification images. We note that all M{3xP3-RFP.attp} transgenes (n=4), all Mi{GFP[E.3xP3]=ET1} transgenes (n=3), and all Tl{GFP[3xP3.cLa]=CRIMIC.TG4} transgenes (n=6) that we assayed labeled the CNS in a manner similar to that detailed here for the indicated lines. We note that we saw no GFP CNS expression in the TI{GFP[3xP3.cLa]=KozakGAL4}spag4[CR70688-KO-kG4]/SM6a line. All lines that we tested are listed below:</p><p><bold>Mi{GFP[E.3xP3]=ET1} transgenes tested:</bold> y[1] w[67c23]; Mi{GFP[E.3xP3]=ET1}MB00051: BDSC-22685 y[1] w[67c23]; Mi{GFP[E.3xP3]=ET1}MB00056: BDSC-22686 w[1118]; Mi{GFP[E.3xP3]=ET1}Ppn[MB07666]: BDSC 25277</p><p><bold>Tl{GFP[3xP3.cLa]=CRIMIC.TG4} transgenes tested:</bold>y[1] w[*]; TI{GFP[3xP3.cLa]=CRIMIC.TG4.0}mfr[CR70821-TG4.0]: BDSC 98524: y[1] w[*]; TI{GFP[3xP3.cLa]=CRIMIC.TG4.0}lace[CR70094-TG4.0]/SM6: BDSC 92702 y[1] w[*] TI{GFP[3xP3.cLa]=CRIMIC.TG4.2}schlank[CR01622-TG4.2] Josd[CR01622-TG4.2-X]/FM7: BDSC 91266 y[1] w[*]; TI{GFP[3xP3.cLa]=CRIMIC.TG4.0}bwa[CR02807-TG4.0]/SM6a; BDSC 97620 y[1] w[*]; TI{GFP[3xP3.cLa]=CRIMIC.TG4.2}ifc[CR70115-TG4.2]/SM6a; BDSC 92710 y[1] w[*]; TI{GFP[3xP3.cLa]=CRIMIC.TG4.1}ghi[CR01805-TG4.1]/TM3; BDSC 92656</p><p><bold>M{3xP3-RFP.attp} transgenes tested</bold> M{3xP3-RFP.attP}ZH-2A: Derived from BDSC 24480 M{3xP3-RFP.attP’}ZH-22A: Derived from BDSC 24481 M{3xP3-RFP.attP’}ZH-51C: Derived from BDSC 24482 {3xP3-RFP.attP}ZH-51D: Derived from BDSC 24483</p></caption>
<graphic xlink:href="573836v4_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4.</label>
<caption><title>Newly generated FABP antibody labels cortex glia.</title> <p>Ventral views of the brain and ventral nerve cord of wild-type larvae that express Myr-GFP under the control of cortex-specific GAL4 driver line <italic>GMR54H02</italic>. Myr-GFP (green) highlights the cell membranes of cortex glia; FABP protein expression (red) exhibits significant overlap with Myr-GFP. Anterior is up; scale bar is 50 microns.</p></caption>
<graphic xlink:href="573836v4_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5.</label>
<caption><title>Loss of <italic>ifc</italic> function reduces optic lobe size and optic lobe neuroblast number.</title> <p>Ventral view of single brain hemisphere of late-third instar larvae of the indicated genotype labeled for neuroblasts (DPN; green), glia (RFP, red), and neurons (ELAV, blue). Loss of function in <italic>ifc</italic> results in reduction of the number of optic lobe neuroblasts (brackets) and the size of the optic lobe (dotted circles) relative to wild-type and <italic>ifc</italic> mutants in which <italic>schlank</italic> function is inhibited specifically in glia (<italic>repo-GAL4&gt;UAS-schlank<sup>RNAi</sup>).</italic> Anterior is up; scale bar is 50 microns.</p></caption>
<graphic xlink:href="573836v4_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Figure S6.</label>
<caption><title>Loss of <italic>ifc</italic> increases RFP fluorescence and induces the formation of bright RFP-positive puncta or aggregates.</title> <p>A-B) Ventral views of the CNS of wildtype (A) and <italic>ifc</italic> mutant (B) late third instar larvae homozygous for the <italic>M{3xP3-RFP.attP}</italic> transgene, which drives RFP expression in most glia. RFP expression is shown in greyscale. Larvae were fixed at the same time in the same tube, mounted on the same slide, and imaged at the same time using identical parameters. <italic>ifc</italic> mutant larvae consistently exhibit higher levels of RFP expression. Anterior is up; scale bar is 100 microns. C-F) High magnification ventral views of the abdominal region of the ventral nerve cord (C and D) and brain (E and F) of wildtype (C and E) and <italic>ifc</italic> mutant larvae (D and F) showing RFP expression in greyscale. Note that the gain was increased in wildtype larvae (C and E) relative to <italic>ifc</italic> mutant larvae (D and F) to enable visualization of RFP signal in the wildtype CNS. Brightly fluorescent puncta or aggregates (arrows) appear in cortex glia of <italic>ifc</italic> mutant, but not wild-type larvae. Anterior is up. Scale bar is 50 microns for C-F. G) Quantification of relative RFP intensity between wild type and <italic>ifc</italic> mutant larvae – p&lt;2.0×10<sup>-4</sup>.</p></caption>
<graphic xlink:href="573836v4_figs6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Figure S7.</label>
<caption><title><italic>ifc<sup>js1</sup></italic> and <italic>ifc<sup>js2</sup></italic> alleles drive cortex glia swelling, ER expansion in cortex glia, and neuronal cell death.</title> <p>A-C) Abdominal segments of dissected ventral nerve cords from late-third instar larvae of the indicated genotype labeled for FABP to label cortex glia and ELAV to label neurons (A-A’’) or FABP and the ER-marker Calnexin-99A (CNX99A; B-B’’). As observed in <italic>ifc<sup>js3</sup></italic>/<italic>ifc-KO</italic> larvae, <italic>ifc<sup>js1</sup></italic> and <italic>ifc<sup>js2</sup></italic> larvae exhibited swollen cortex glia (A-B) and an expanded ER phenotype in cortex glia as indicated by elevated CNX99A expression (B). (C-C’’’) <italic>ifc<sup>js1</sup></italic> and <italic>ifc<sup>js1</sup></italic>/<italic>ifc<sup>js2</sup></italic>larvae also exhibit enhanced presence of the neuronal cell death marker cleaved Caspase 3 (CC3). Note that the chromosome that harbors the <italic>ifc<sup>js2</sup></italic> chromosome also harbors a mutation in the pro-apoptotic gene, <italic>Dark</italic>. Therefore, to track the impact of <italic>ifc<sup>js2</sup></italic>on neuronal cell death, we assessed neuronal cell death in larvae trans-heterozygous for <italic>ifc<sup>js1</sup></italic> and <italic>ifc<sup>js2</sup></italic> (Civ). Scale bar is 50 microns.</p></caption>
<graphic xlink:href="573836v4_figs7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs8" position="float" orientation="portrait" fig-type="figure">
<label>Figure S8.</label>
<caption><title>Reduction of cortex glia number in <italic>ifc<sup>-/-</sup></italic> larvae results from increased apoptosis and reduced cell proliferation.</title> <p>A-B) Thoracic regions of the CNS of larvae of the indicated genotype labeled for ELAV (magenta) to label neurons and FABP (green) to label cortex glia. C) Number of cortex glia in the thoracic region of larvae of the indicated genotype; *** denotes p value less than 3 x 10<sup>-4</sup>. D) Number of phospho-Histone H3 positive glia in the thoracic region of larvae of the indicated genotype; ** denotes p value of less than 0.01.</p></caption>
<graphic xlink:href="573836v4_figs8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs9" position="float" orientation="portrait" fig-type="figure">
<label>Figure S9.</label>
<caption><title>Glial-specific expression of <italic>ifc</italic> completely rescues the CNS phenotype of <italic>ifc</italic> mutant larvae.</title> <p>Ventral views of the CNS from <italic>ifc</italic> mutant larvae (left) and <italic>ifc</italic> mutant larvae in which a wild-type <italic>ifc</italic> transgene is driven specifically in glia under the control of <italic>repo-GAL4</italic> (middle and right panels). Each CNS is labeled for neuroblasts in green (DPN) and neurons in red (ELAV). Note the strong rescue of the CNS elongation and reduction of optic lobe size (dotted circles) and neuroblast number (arrows) observed in <italic>ifc</italic> mutant larvae relative to those that express <italic>ifc</italic> in glia. Anterior is up; scale bar is 50 microns.</p></caption>
<graphic xlink:href="573836v4_figs9.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs10" position="float" orientation="portrait" fig-type="figure">
<label>Figure S10.</label>
<caption><title><italic>ifc</italic> is predominately expressed in glia and Ifc protein mildly localizes to the Golgi where mild expansion appears to occur in the larval CNS.</title> <p>A-B) Ventral (A-A’’) and dorsal (B-B’’) views of the CNS of late-third instar wild-type larvae labeled for <italic>ifc-GAL4&gt;nRFP</italic> (magenta; A’-B’), REPO to mark glia (green; A), and ELAV to mark neurons (green; B). C-D) High magnification ventral views of thoracic segments in the CNS of wild-type late third instar larvae labeled for GFP (green; C and D), GOLGIN84 (magenta; C’), GOLGIN245 (magenta; D’). E-F) Late third instar larvae labeled for 3xP3-RFP (green; E and F), GOLGIN245 (magenta; E’ and F’). Anterior is up; scale bar is 30μm for all panels.</p></caption>
<graphic xlink:href="573836v4_figs10.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs11" position="float" orientation="portrait" fig-type="figure">
<label>Figure S11.</label>
<caption><title>ER chaperones are mostly downregulated, and genes involved the Lands cycle are mostly upregulated in the CNS of <italic>ifc<sup>-/-</sup></italic>mutant larvae.</title> <p>A) Four of the five ER chaperones in <italic>Drosophila</italic> (Schroder &amp; Kaufman, 2006; Ryoo et al., 2007) are significantly downregulated in transcription, suggesting an atypical unfolded protein response (UPR) following the transcriptional upregulation of <italic>Xbp-1s</italic> in the <italic>ifc</italic>-deprived CNS of <italic>ifc</italic> mutant larvae. B) Schematic of the Lands cycle that functions in the acyl chain remodeling of membrane phospholipids. C-D) Most genes participating in the assembly (C) and removal (D) of acyl chains in the Lands cycle are significantly upregulated.</p></caption>
<graphic xlink:href="573836v4_figs11.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs12" position="float" orientation="portrait" fig-type="figure">
<label>Figure S12.</label>
<caption><title>Glial-specific inhibition of <italic>schlank</italic> suppresses the <italic>ifc</italic> swollen cortex glia phenotype.</title> <p>High magnification X-Y, X-Z, and Y-Z views of the abdominal region of the ventral nerve cord of late third instar of the indicated genotype. FABP staining (green) labels cortex glia; CNX99A staining (red) labels ER. The swollen cortex glia in <italic>ifc</italic> mutant larvae (arrows) are not apparent in either wild-type larvae or <italic>ifc</italic> mutant larvae in which <italic>schlank</italic> function was inhibited specifically in glia (<italic>ifc<sup>-/-</sup>; repo-GAL4/UAS-schlank<sup>RNAi</sup></italic>). Anterior is up; scale bar is 20μm.</p></caption>
<graphic xlink:href="573836v4_figs12.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs13" position="float" orientation="portrait" fig-type="figure">
<label>Figure S13.</label>
<caption><title>Glial-specific, but not neuronal-specific, knockdown of <italic>ifc</italic> drives neuronal cell death.</title> <p>Low (A-C) and high (A’-C’’) magnification views of the ventral nerve cord of late-third instar larvae of the indicated genotype labeled for ELAV (magenta or greyscale) and Cleaved Caspase-3 (green). Arrows point to regions marked by Cleaved Caspase-3 staining and/or apparent neuronal cell death identified by circular perforations in the neuronal cell layer. Please note that the <italic>repoGAL80</italic> transgene is present in <italic>elav&gt;ifc RNAi</italic> larvae to block GAL4 function in glia (panel B-B’’). Anterior is up in all panels; scale bar is 50μm for panels A-C and 10μm for panels A’-C’’. Full genotypes of the larvae used in this experiment are as follows – A: <italic>UAS-ifc-RNAi/+</italic>; B: <italic>elavGAL4/+; repoGAL80/+; UAS-ifc-RNAi/+</italic>; C: <italic>repoGAL4/UAS-ifc-RNAi</italic>. D) Quantification of the number of Cleaved Caspase-3 positive neurons in the thorax region of the ventral nerve cord in control, neuronal-specific knockdown of <italic>ifc</italic>, and glial-specific knockdown of <italic>ifc</italic> L3 larvae.</p></caption>
<graphic xlink:href="573836v4_figs13.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs14" position="float" orientation="portrait" fig-type="figure">
<label>Figure S14.</label>
<caption><title>Subperineurial glial cell membranes encircle dying neurons in <italic>ifc</italic> mutant larvae.</title> <p>High magnification ventral views of the brain of wild-type (top) and <italic>ifc</italic> mutant (bottom) larvae labeled for Myr-GFP to mark the membranes of subperineurial glia (green, left panels), Death caspase protein-1 (DCP-1) to label dying neurons (red, left panels), and ELAV to mark neurons and the neuronal cell layer (blue, left panels). Arrows identify DCP-1 positive dying neurons, which are encircled by GFP-positive glial cell membranes in <italic>ifc</italic> mutant, but not wild-type, backgrounds. Anterior is up; scale bar is 10 microns. DCP-1 antibody obtained from Cell Signaling Technologies (Ab #9578)</p></caption>
<graphic xlink:href="573836v4_figs14.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption><title>Genotype of flies in <xref rid="fig2" ref-type="fig">figures 2</xref> &amp; <xref rid="fig3" ref-type="fig">3</xref></title></caption>
<graphic xlink:href="573836v4_tbl1.tif" mimetype="image" mime-subtype="tiff"/>
</table-wrap>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank the Iowa Developmental Studies Hybridoma Bank for antibodies, and the Bloomington Stock Center, Vienna Drosophila Research Center, FlyORF, and the National Institutes of Genetics stock center in Japan for countless fly lines. We thank Drs. Christian Klambt, Chih-Chiang Chan, Dion Dickman for reagents. We thank Dr. Tristan Qingyuan Li for comments on the manuscript. We thank the Genome Technology Access Center at Washington University for next-generation sequencing and analysis of RNA-seq samples. We thank Dr. Sanja Sviben, Gregory Strout, and John Wulf II for assistance in TEM studies conducted at the Washington University Center for Cellular Imaging, which is supported in part by Washington University School of Medicine, The Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (CDI-CORE-2015-505 and CDI-CORE-2019-813), the Foundation for Barnes-Jewish Hospital (3770) and the Washington University Diabetes Research Center (NIH P30 DK020579).</p>
</ack>
<sec id="d1e2090" sec-type="additional-information">
<title>Additional information</title>
<sec id="s4"><title>Author Contributions</title>
<p>BAW, HL, Yi Zhu, and JBS completed the genetic screen that identified the <italic>ifc</italic> alleles and completed the initial genetic characterization of these alleles. Yuqing Zhu, JD, and JBS completed all other experiments except for generating the lipidomics data via mass spectrometry, which were completed by KC and GJP. Yuqing Zhu and JBS wrote the manuscript and compiled figures with help from JD with figures. All authors read, commented on, and edited the manuscript.</p>
</sec>
<sec id="s5">
<title>Funding</title>
<p>This work was supported by grants from the National Institutes of Health (NS036570) to J.B.S., (NS122903) to H.L., and (R35 ES2028365) to G.J.P.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jackman</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Ishii</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Bansal</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Oligodendrocyte development and myelin biogenesis: parsing out the roles of glycosphingolipids</article-title>. <source>Physiology</source>, <volume>24</volume>(<issue>5</issue>), <fpage>290</fpage>–<lpage>297</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghosh</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Kling</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Snaidero</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Sampaio</surname>, <given-names>J. L.</given-names></string-name>, <string-name><surname>Shevchenko</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Gras</surname>, <given-names>H.</given-names></string-name>, <etal>…</etal> <string-name><surname>Simons</surname>, <given-names>M.</given-names></string-name></person-group> (<year>2013</year>). <article-title>A global in vivo <italic>Drosophila</italic> RNAi screen identifies a key role of ceramide phosphoethanolamine for glial ensheathment of axons</article-title>. <source>PLoS genetics</source>, <volume>9</volume>(<issue>12</issue>), <fpage>e1003980</fpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vacaru</surname>, <given-names>A. M.</given-names></string-name>, <string-name><surname>van den Dikkenberg</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Ternes</surname>, <given-names>P.</given-names></string-name>, &amp; <string-name><surname>Holthuis</surname>, <given-names>J. C.</given-names></string-name></person-group> (<year>2013</year>). <article-title>Ceramide Phosphoethanolamine Biosynthesis in <italic>Drosophila</italic> Is Mediated by a Unique Ethanolamine Phosphotransferase in the Golgi Lumen</article-title>. <source>Journal of Biological Chemistry</source>, <volume>288</volume>(<issue>16</issue>), <fpage>11520</fpage>–<lpage>11530</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hannun</surname>, <given-names>Y. A.</given-names></string-name>, &amp; <string-name><surname>Obeid</surname>, <given-names>L. M</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Sphingolipids and their metabolism in physiology and disease</article-title>. <source>Nature reviews Molecular cell biology</source>, <volume>19</volume>(<issue>3</issue>), <fpage>175</fpage>–<lpage>191</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Tang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Taylor</surname>, <given-names>K. G.</given-names></string-name>, <string-name><surname>DuPré</surname>, <given-names>D. B.</given-names></string-name>, &amp; <string-name><surname>Yappert</surname>, <given-names>M. C</given-names></string-name></person-group>. (<year>2002</year>). <article-title>Conformational characterization of ceramides by nuclear magnetic resonance spectroscopy</article-title>. <source>Biophysical journal</source>, <volume>82</volume>(<issue>4</issue>), <fpage>2067</fpage>–<lpage>2080</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yasuda</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Al Sazzad</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Jäntti</surname>, <given-names>N. Z.</given-names></string-name>, <string-name><surname>Pentikäinen</surname>, <given-names>O. T.</given-names></string-name>, &amp; <string-name><surname>Slotte</surname>, <given-names>J. P.</given-names></string-name></person-group> (<year>2016</year>). <article-title>The influence of hydrogen bonding on sphingomyelin/colipid interactions in bilayer membranes</article-title>. <source>Biophysical Journal</source>, <volume>110</volume>(<issue>2</issue>), <fpage>431</fpage>–<lpage>440</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dolgin</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Straussberg</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Mileva</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Yogev</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Khoury</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Konen</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Barhum</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zvulunov</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Mao</surname>, <given-names>C.</given-names></string-name> &amp; <string-name><surname>Birk</surname>, <given-names>O. S</given-names></string-name></person-group>. (<year>2019</year>). <article-title><italic>DEGS1</italic> variant causes neurological disorder</article-title>. <source>European Journal of Human Genetics</source>, <volume>27</volume>(<issue>11</issue>), <fpage>1668</fpage>–<lpage>1676</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karsai</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Kraft</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Haag</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Korenke</surname>, <given-names>G. C.</given-names></string-name>, <string-name><surname>Hänisch</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Othman</surname>, <given-names>A.</given-names></string-name>, <etal>…</etal> <string-name><surname>Kurth</surname>, <given-names>I.</given-names></string-name></person-group> (<year>2019</year>). <article-title>DEGS1-associated aberrant sphingolipid metabolism impairs nervous system function in humans</article-title>. <source>The Journal of clinical investigation</source>, <volume>129</volume>(<issue>3</issue>), <fpage>1229</fpage>–<lpage>1239</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pant</surname>, <given-names>D. C.</given-names></string-name>, <string-name><surname>Dorboz</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Schluter</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Fourcade</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Launay</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Joya</surname>, <given-names>J.</given-names></string-name>, <etal>…</etal> <string-name><surname>Pujol</surname>, <given-names>A.</given-names></string-name></person-group> (<year>2019</year>). <article-title>Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy</article-title>. <source>The Journal of clinical investigation</source>, <volume>129</volume>(<issue>3</issue>), <fpage>1240</fpage>–<lpage>1256</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fyrst</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Herr</surname>, <given-names>D. R.</given-names></string-name>, <string-name><surname>Harris</surname>, <given-names>G. L.</given-names></string-name>, &amp; <string-name><surname>Saba</surname>, <given-names>J. D</given-names></string-name></person-group>. (<year>2004</year>). <article-title>Characterization of free endogenous C14 and C16 sphingoid bases from <italic>Drosophila melanogaster</italic></article-title>. <source>Journal of lipid research</source>, <volume>45</volume>(<issue>1</issue>), <fpage>54</fpage>–<lpage>62</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Acharya</surname>, <given-names>U.</given-names></string-name>, &amp; <string-name><surname>Acharya</surname>, <given-names>J. K</given-names></string-name></person-group>. (<year>2005</year>). <article-title>Enzymes of sphingolipid metabolism in <italic>Drosophila melanogaster</italic></article-title>. <source>Cellular and Molecular Life Sciences CMLS</source>, <volume>62</volume>, <fpage>128</fpage>–<lpage>142</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dunn</surname>, <given-names>T. M.</given-names></string-name>, <string-name><surname>Tifft</surname>, <given-names>C. J.</given-names></string-name>, &amp; <string-name><surname>Proia</surname>, <given-names>R. L</given-names></string-name></person-group>. (<year>2019</year>). <article-title>A perilous path: the inborn errors of sphingolipid metabolism</article-title>. <source>Journal of lipid research</source>, <volume>60</volume>(<issue>3</issue>), <fpage>475</fpage>–<lpage>483</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Dutta</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Bellen</surname>, <given-names>H. J</given-names></string-name></person-group>. (<year>2023</year>). <article-title>Sphingolipids in neurodegenerative diseases</article-title>. <source>Frontiers in Neuroscience</source>, <volume>17</volume>, <fpage>1137893</fpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kumagai</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Yasuda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Okemoto</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Nishijima</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kobayashi</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Hanada</surname>, <given-names>K</given-names></string-name></person-group>. (<year>2005</year>). <article-title>CERT mediates intermembrane transfer of various molecular species of ceramides</article-title>. <source>Journal of Biological Chemistry</source>, <volume>280</volume>(<issue>8</issue>), <fpage>6488</fpage>–<lpage>6495</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kobayashi</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name><surname>Menon</surname>, <given-names>A. K</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Transbilayer lipid asymmetry</article-title>. <source>Current Biology</source>, <volume>28</volume>(<issue>8</issue>), <fpage>R386</fpage>–<lpage>R391</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holland</surname>, <given-names>W. L.</given-names></string-name>, <string-name><surname>Brozinick</surname>, <given-names>J. T.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L. P.</given-names></string-name>, <string-name><surname>Hawkins</surname>, <given-names>E. D.</given-names></string-name>, <string-name><surname>Sargent</surname>, <given-names>K. M.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <etal>…</etal> <string-name><surname>Summers</surname>, <given-names>S. A.</given-names></string-name></person-group> (<year>2007</year>). <article-title>Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance</article-title>. <source>Cell metabolism</source>, <volume>5</volume>(<issue>3</issue>), <fpage>167</fpage>–<lpage>179</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname>, <given-names>W. H.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>C. C.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>Y. L.</given-names></string-name>, <string-name><surname>Chang</surname>, <given-names>Y. C.</given-names></string-name>, <string-name><surname>Lien</surname>, <given-names>W. Y.</given-names></string-name>, <string-name><surname>Chao</surname>, <given-names>H. C.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>S.Y.</given-names></string-name>, <string-name><surname>Kuo</surname>, <given-names>C.H.</given-names></string-name>, <string-name><surname>Ho</surname>, <given-names>H.C.</given-names></string-name>, &amp; <string-name><surname>Chan</surname>, <given-names>C. C</given-names></string-name></person-group>. (<year>2017</year>). <article-title>Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation <italic>in vivo</italic></article-title>. <source>EMBO reports</source>, <volume>18</volume>(<issue>7</issue>), <fpage>1150</fpage>–<lpage>1165</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lone</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Aaltonen</surname>, <given-names>M. J.</given-names></string-name>, <string-name><surname>Zidell</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pedro</surname>, <given-names>H. F.</given-names></string-name>, <string-name><surname>Saute</surname>, <given-names>J. A. M.</given-names></string-name>, <string-name><surname>Mathew</surname>, <given-names>S.</given-names></string-name>, <etal>…</etal> <string-name><surname>Hornemann</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2022</year>). <article-title>SPTLC1 variants associated with ALS produce distinct sphingolipid signatures through impaired interaction with ORMDL proteins</article-title>. <source>The Journal of Clinical Investigation</source>, <volume>132</volume>(<issue>18</issue>):<fpage>e161908</fpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lone</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Zeng</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bourquin</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>Z.</given-names></string-name>, <etal>…</etal> <string-name><surname>Hornemann</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2023</year>). <article-title>SPTLC1 p. Leu38Arg, a novel mutation associated with childhood ALS</article-title>. <source>Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids</source>, <fpage>159359</fpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Syeda</surname>, <given-names>S. B.</given-names></string-name>, <string-name><surname>Lone</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Mohassel</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Donkervoort</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Munot</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>França</surname>, <given-names>M. C.</given-names></string-name>, <etal>…</etal> <string-name><surname>Bönnemann</surname>, <given-names>C. G.</given-names></string-name></person-group> (<year>2024</year>). <article-title>Recurrent <italic>de novo</italic> SPTLC2 variant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis</article-title>. <source>Journal of Neurology, Neurosurgery &amp; Psychiatry</source>. <volume>95</volume>(<issue>2</issue>):<fpage>103</fpage>–<lpage>113</lpage></mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dohrn</surname>, <given-names>M. F.</given-names></string-name>, <string-name><surname>Beijer</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Lone</surname>, <given-names>M. A.</given-names></string-name>, <string-name><surname>Bayraktar</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Oflazer</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Orbach</surname>, <given-names>R.</given-names></string-name>, <etal>…</etal> <string-name><surname>Zuchner</surname>, <given-names>S.</given-names></string-name></person-group> (<year>2024</year>). <article-title>Recurrent de-novo gain-of-function mutation in SPTLC2 confirms dysregulated sphingolipid production to cause juvenile amyotrophic lateral sclerosis. <italic>Journal of Neurology</italic></article-title>, <source>Neurosurgery &amp; Psychiatry</source>. <volume>95</volume>(<issue>3</issue>):<fpage>201</fpage>–<lpage>205</lpage></mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Srivastava</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shaked</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Gable</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Pan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Somashekarappa</surname> <given-names>N</given-names></string-name>, <etal>…</etal> <string-name><surname>Dunn</surname> <given-names>TM</given-names></string-name></person-group>. (<year>2023</year>). <article-title>SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia</article-title>. <source>Brain</source>. <volume>146</volume>(<issue>4</issue>):<fpage>1420</fpage>–<lpage>1435</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freeman</surname>, <given-names>M. R.</given-names></string-name>, &amp; <string-name><surname>Doherty</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2006</year>). <article-title>Glial cell biology in <italic>Drosophila</italic> and vertebrates</article-title>. <source>Trends in neurosciences</source>, <volume>29</volume>(<issue>2</issue>), <fpage>82</fpage>–<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coutinho-Budd</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Freeman</surname>, <given-names>M. R</given-names></string-name></person-group>. (<year>2013</year>). <article-title>Probing the enigma: unraveling glial cell biology in invertebrates</article-title>. <source>Current opinion in neurobiology</source>, <volume>23</volume>(<issue>6</issue>), <fpage>1073</fpage>–<lpage>1079</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yildirim</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Petri</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kottmeier</surname>, <given-names>R.</given-names></string-name>, &amp; <string-name><surname>Klämbt</surname>, <given-names>C</given-names></string-name></person-group>. (<year>2019</year>). <article-title>Drosophila glia: Few cell types and many conserved functions</article-title>. <source>Glia</source>, <volume>67</volume>(<issue>1</issue>), <fpage>5</fpage>–<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corty</surname>, <given-names>M. M.</given-names></string-name>, &amp; <string-name><surname>Coutinho-Budd</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2023</year>). <article-title><italic>Drosophila</italic> glia take shape to sculpt the nervous system</article-title>. <source>Current Opinion in Neurobiology</source>, <volume>79</volume>, <fpage>102689</fpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stork</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Engelen</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Krudewig</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Silies</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bainton</surname>, <given-names>R. J.</given-names></string-name>, &amp; <string-name><surname>Klämbt</surname>, <given-names>C</given-names></string-name></person-group>. (<year>2008</year>). <article-title>Organization and function of the blood–brain barrier in <italic>Drosophila</italic></article-title>. <source>Journal of Neuroscience</source>, <volume>28</volume>(<issue>3</issue>), <fpage>587</fpage>–<lpage>597</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Volkenhoff</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Weiler</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Letzel</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Stehling</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Klämbt</surname>, <given-names>C.</given-names></string-name>, &amp; <string-name><surname>Schirmeier</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2015</year>). <article-title>Glial glycolysis is essential for neuronal survival in Drosophila</article-title>. <source>Cell metabolism</source>, <volume>22</volume>(<issue>3</issue>), <fpage>437</fpage>–<lpage>447</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Freeman</surname>, <given-names>M. R</given-names></string-name></person-group>. (<year>2015</year>). <article-title><italic>Drosophila</italic> central nervous system glia</article-title>. <source>Cold Spring Harbor perspectives in biology</source>, <volume>7</volume>(<issue>11</issue>), <fpage>a020552</fpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kis</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Barti</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Lippai</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Sass</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2015</year>). <article-title>Specialized cortex glial cells accumulate lipid droplets in <italic>Drosophila melanogaster</italic></article-title>. <source>PLoS One</source>, <volume>10</volume>(<issue>7</issue>), <fpage>e0131250</fpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kremer</surname>, <given-names>M. C.</given-names></string-name>, <string-name><surname>Jung</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Batelli</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Rubin</surname>, <given-names>G. M.</given-names></string-name>, &amp; <string-name><surname>Gaul</surname>, <given-names>U</given-names></string-name></person-group>. (<year>2017</year>). <article-title>The glia of the adult <italic>Drosophila</italic> nervous system</article-title>. <source>Glia</source>, <volume>65</volume>(<issue>4</issue>), <fpage>606</fpage>–<lpage>638</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pfeiffer</surname>, <given-names>B. D.</given-names></string-name>, <string-name><surname>Ngo</surname>, <given-names>T. T. B.</given-names></string-name>, <string-name><surname>Hibbard</surname>, <given-names>K. L.</given-names></string-name>, <string-name><surname>Murphy</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jenett</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Truman</surname>, <given-names>J. W.</given-names></string-name>, &amp; <string-name><surname>Rubin</surname>, <given-names>G. M</given-names></string-name></person-group>. (<year>2010</year>). <article-title>Refinement of tools for targeted gene expression in Drosophila</article-title>. <source>Genetics</source>, <volume>186</volume>(<issue>2</issue>), <fpage>735</fpage>–<lpage>755</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nern</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pfeiffer</surname>, <given-names>B. D.</given-names></string-name>, &amp; <string-name><surname>Rubin</surname>, <given-names>G. M</given-names></string-name></person-group>. (<year>2015</year>). <article-title>Optimized tools for multicolor stochastic labeling reveal diverse stereotyped cell arrangements in the fly visual system</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <volume>112</volume>(<issue>22</issue>), <fpage>E2967</fpage>–<lpage>E2976</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Southall</surname>, <given-names>T. D.</given-names></string-name>, <string-name><surname>Gold</surname>, <given-names>K. S.</given-names></string-name>, <string-name><surname>Egger</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Davidson</surname>, <given-names>C. M.</given-names></string-name>, <string-name><surname>Caygill</surname>, <given-names>E. E.</given-names></string-name>, <string-name><surname>Marshall</surname>, <given-names>O. J.</given-names></string-name>, &amp; <string-name><surname>Brand</surname>, <given-names>A. H</given-names></string-name></person-group>. (<year>2013</year>). <article-title>Cell-type-specific profiling of gene expression and chromatin binding without cell isolation: assaying RNA Pol II occupancy in neural stem cells</article-title>. <source>Developmental cell</source>, <volume>26</volume>(<issue>1</issue>), <fpage>101</fpage>–<lpage>112</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berger</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Renner</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Lüer</surname>, <given-names>K.</given-names></string-name>, &amp; <string-name><surname>Technau</surname>, <given-names>G. M</given-names></string-name></person-group>. (<year>2007</year>). <article-title>The commonly used marker ELAV is transiently expressed in neuroblasts and glial cells in the Drosophila embryonic CNS</article-title>. <source>Developmental dynamics: an official publication of the American Association of Anatomists</source>, <volume>236</volume>(<issue>12</issue>), <fpage>3562</fpage>–<lpage>3568</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lacin</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>DiPaola</surname>, <given-names>J. T.</given-names></string-name>, <string-name><surname>Wilson</surname>, <given-names>B. A.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name><surname>Skeath</surname>, <given-names>J. B</given-names></string-name></person-group>. (<year>2024</year>). <article-title>A genetic screen in Drosophila uncovers a role for senseless-2 in surface glia in the peripheral nervous system to regulate CNS morphology</article-title>. <source>G3: Genes, Genomes, Genetics</source>, <volume>14</volume>(<issue>9</issue>), <fpage>jkae152</fpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ziegler</surname>, <given-names>A. B.</given-names></string-name>, <string-name><surname>Brüsselbach</surname>, <given-names>F.</given-names></string-name>, &amp; <string-name><surname>Hovemann</surname>, <given-names>B. T</given-names></string-name></person-group>. (<year>2013</year>). <article-title>Activity and coexpression of <italic>Drosophila</italic> black with ebony in fly optic lobes reveals putative cooperative tasks in vision that evade electroretinographic detection</article-title>. <source>Journal of Comparative Neurology</source>, <volume>521</volume>(<issue>6</issue>), <fpage>1207</fpage>–<lpage>1224</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Binari</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Falo-Sanjuan</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Perrimon</surname>, <given-names>N</given-names></string-name></person-group>. (<year>2019</year>). <article-title>In vivo study of gene expression with an enhanced dual-color fluorescent transcriptional timer</article-title>. <source>eLife</source>, <volume>8</volume>, <elocation-id>e46181</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.46181</pub-id></mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sarov</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Barz</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jambor</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Hein</surname>, <given-names>M. Y.</given-names></string-name>, <string-name><surname>Schmied</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Suchold</surname>, <given-names>D.</given-names></string-name>, <etal>…</etal> <string-name><surname>Schnorrer</surname>, <given-names>F.</given-names></string-name></person-group> (<year>2016</year>). <article-title>A genome-wide resource for the analysis of protein localisation in <italic>Drosophila</italic></article-title>. <source>eLife</source>, <volume>5</volume>, <elocation-id>e12068</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.12068</pub-id></mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bergeron</surname>, <given-names>J. J.</given-names></string-name>, <string-name><surname>Brenner</surname>, <given-names>M. B.</given-names></string-name>, <string-name><surname>Thomas</surname>, <given-names>D. Y.</given-names></string-name>, &amp; <string-name><surname>Williams</surname>, <given-names>D. B</given-names></string-name></person-group>. (<year>1994</year>). <article-title>Calnexin: a membrane-bound chaperone of the endoplasmic reticulum</article-title>. <source>Trends in biochemical sciences</source>, <volume>19</volume>(<issue>3</issue>), <fpage>124</fpage>–<lpage>128</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kikuma</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Sutter</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Dickman</surname>, <given-names>D. K</given-names></string-name></person-group>. (<year>2017</year>). <article-title>Extended synaptotagmin localizes to presynaptic ER and promotes neurotransmission and synaptic growth in Drosophila</article-title>. <source>Genetics</source>, <volume>207</volume>(<issue>3</issue>), <fpage>993</fpage>–<lpage>1006</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>, <given-names>S. Y.</given-names></string-name>, <string-name><surname>Muschalik</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Chadwick</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Munro</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2022</year>). <article-title><italic>In vivo</italic> characterization of <italic>Drosophila</italic> golgins reveals redundancy and plasticity of vesicle capture at the Golgi apparatus</article-title>. <source>Current Biology</source>, <volume>32</volume>(<issue>21</issue>), <fpage>4549</fpage>–<lpage>4564</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawano</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kumagai</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Nishijima</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Hanada</surname>, <given-names>K</given-names></string-name></person-group>. (<year>2006</year>). <article-title>Efficient trafficking of ceramide from the endoplasmic reticulum to the Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif of CERT</article-title>. <source>Journal of Biological Chemistry</source>, <volume>281</volume>(<issue>40</issue>), <fpage>30279</fpage>–<lpage>30288</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grabner</surname>, <given-names>G. F.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Schweiger</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Zechner</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Lipolysis: cellular mechanisms for lipid mobilization from fat stores</article-title>. <source>Nature metabolism</source>, <volume>3</volume>(<issue>11</issue>), <fpage>1445</fpage>–<lpage>1465</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberlé</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Hegarty</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Bossard</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ferré</surname>, <given-names>P.</given-names></string-name>, &amp; <string-name><surname>Foufelle</surname>, <given-names>F</given-names></string-name></person-group>. (<year>2004</year>). <article-title>SREBP transcription factors: master regulators of lipid homeostasis</article-title>. <source>Biochimie</source>, <volume>86</volume>(<issue>11</issue>), <fpage>839</fpage>–<lpage>848</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Osborne</surname>, <given-names>T. F.</given-names></string-name>, &amp; <string-name><surname>Espenshade</surname>, <given-names>P. J</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it’s been</article-title>. <source>Genes &amp; development</source>, <volume>23</volume>(<issue>22</issue>), <fpage>2578</fpage>–<lpage>2591</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jacquemyn</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cascalho</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Goodchild</surname>, <given-names>R. E</given-names></string-name></person-group>. (<year>2017</year>). <article-title>The ins and outs of endoplasmic reticulum-controlled lipid biosynthesis</article-title>. <source>EMBO reports</source>, <volume>18</volume>(<issue>11</issue>), <fpage>1905</fpage>–<lpage>1921</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sriburi</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Bommiasamy</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Buldak</surname>, <given-names>G. L.</given-names></string-name>, <string-name><surname>Robbins</surname>, <given-names>G. R.</given-names></string-name>, <string-name><surname>Frank</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Jackowski</surname>, <given-names>S.</given-names></string-name>, &amp; <string-name><surname>Brewer</surname>, <given-names>J. W</given-names></string-name></person-group>. (<year>2007</year>). <article-title>Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1 (S)-induced endoplasmic reticulum biogenesis</article-title>. <source>Journal of Biological Chemistry</source>, <volume>282</volume>(<issue>10</issue>), <fpage>7024</fpage>–<lpage>7034</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernales</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Papa</surname>, <given-names>F. R.</given-names></string-name>, &amp; <string-name><surname>Walter</surname>, <given-names>P</given-names></string-name></person-group>. (<year>2006</year>). <article-title>Intracellular signaling by the unfolded protein response</article-title>. <source>Annu. Rev. Cell Dev. Biol</source>., <volume>22</volume>, <fpage>487</fpage>–<lpage>508</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moessinger</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Klizaite</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Steinhagen</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Philippou-Massier</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shevchenko</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hoch</surname>, <given-names>M.</given-names></string-name>, <etal>…</etal> <string-name><surname>Thiele</surname>, <given-names>C.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Two different pathways of phosphatidylcholine synthesis, the Kennedy Pathway and the Lands Cycle, differentially regulate cellular triacylglycerol storage</article-title>. <source>BMC cell biology</source>, <volume>15</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>17</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moessinger</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kuerschner</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Spandl</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shevchenko</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Thiele</surname>, <given-names>C</given-names></string-name></person-group>. (<year>2011</year>). <article-title>Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine</article-title>. <source>Journal of Biological Chemistry</source>, <volume>286</volume>(<issue>24</issue>), <fpage>21330</fpage>–<lpage>21339</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harayama</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Eto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Shindou</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kita</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Otsubo</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Hishikawa</surname>, <given-names>D.</given-names></string-name>, <etal>…</etal> <string-name><surname>Shimizu</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2014</year>). <article-title>Lysophospholipid acyltransferases mediate phosphatidylcholine diversification to achieve the physical properties required in vivo</article-title>. <source>Cell metabolism</source>, <volume>20</volume>(<issue>2</issue>), <fpage>295</fpage>–<lpage>305</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Donnell</surname>, <given-names>V. B</given-names></string-name></person-group>. (<year>2022</year>). <article-title>New appreciation for an old pathway: the Lands Cycle moves into new arenas in health and disease</article-title>. <source>Biochemical Society Transactions</source>, <volume>50</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>S. Y.</given-names></string-name>, <string-name><surname>Yoo</surname>, <given-names>S. J.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zapata</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Srinivasan</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hay</surname>, <given-names>B. A.</given-names></string-name>, &amp; <string-name><surname>Baker</surname>, <given-names>N. E</given-names></string-name></person-group>. (<year>2002</year>). <article-title>A pathway of signals regulating effector and initiator caspases in the developing <italic>Drosophila</italic> eye</article-title>. <source>Development</source>,<volume>129</volume>(<issue>13</issue>), <fpage>3269</fpage>–<lpage>3278</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name><surname>Bergmann</surname>, <given-names>A</given-names></string-name></person-group>. (<year>2010</year>). <article-title>The cleaved-Caspase-3 antibody is a marker of Caspase-9-like DRONC activity in <italic>Drosophila</italic></article-title>. <source>Cell Death &amp; Differentiation</source>, <volume>17</volume>(<issue>3</issue>), <fpage>534</fpage>–<lpage>539</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O’Brien</surname>, <given-names>J. S</given-names></string-name></person-group>. (<year>1965</year>). <article-title>Stability of the Myelin Membrane: Lipid molecules may impart stability to the myelin membrane through intermolecular cohesion</article-title>. <source>Science</source>, <volume>147</volume>(<issue>3662</issue>), <fpage>1099</fpage>–<lpage>1107</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marcus</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Popko</surname>, <given-names>B</given-names></string-name></person-group>. (<year>2002</year>). <article-title>Galactolipids are molecular determinants of myelin development and axo–glial organization</article-title>. <source>Biochimica et Biophysica Acta (BBA)-General Subjects</source>, <volume>1573</volume>(<issue>3</issue>), <fpage>406</fpage>–<lpage>413</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harrison</surname>, <given-names>P. J.</given-names></string-name>, <string-name><surname>Dunn</surname>, <given-names>T. M.</given-names></string-name>, &amp; <string-name><surname>Campopiano</surname>, <given-names>D. J</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Sphingolipid biosynthesis in man and microbes</article-title>. <source>Natural product reports</source>, <volume>35</volume>(<issue>9</issue>), <fpage>921</fpage>–<lpage>954</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunduri</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Turner-Evans</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Konya</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Izumi</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Nagashima</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Lockett</surname>, <given-names>S.</given-names></string-name>, <etal>…</etal> <string-name><surname>Acharya</surname>, <given-names>J. K.</given-names></string-name></person-group> (<year>2018</year>). <article-title>Defective cortex glia plasma membrane structure underlies light-induced epilepsy in cpes mutants</article-title>. <source>Proceedings of the National Academy of Sciences</source>, <volume>115</volume>(<issue>38</issue>), <fpage>E8919</fpage>–<lpage>E8928</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarke</surname>, <given-names>B. A.</given-names></string-name>, <string-name><surname>Majumder</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>Y. T.</given-names></string-name>, <string-name><surname>Kono</surname>, <given-names>M.</given-names></string-name>, <etal>…</etal> <string-name><surname>Proia</surname>, <given-names>R. L.</given-names></string-name></person-group> (<year>2019</year>). <article-title>The <italic>Ormdl</italic> genes regulate the sphingolipid synthesis pathway to ensure proper myelination and neurologic function in mice</article-title>. <source>eLife</source>, <volume>8</volume>, <elocation-id>e51067</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.51067</pub-id></mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zuo</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Byeon</surname>, <given-names>S. K.</given-names></string-name>, <string-name><surname>Pandey</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Bellen</surname>, <given-names>H. J</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia</article-title>. <source>Science Advances</source>, <volume>8</volume>(<issue>28</issue>), <fpage>eabn3326</fpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Beachum</surname> <given-names>AN</given-names></string-name>, <string-name><surname>Salazar</surname> <given-names>G</given-names></string-name>, <string-name><surname>Nachbar</surname> <given-names>A</given-names></string-name>, <string-name><surname>Krause</surname> <given-names>K</given-names></string-name>, <string-name><surname>Klose</surname> <given-names>H</given-names></string-name>, <string-name><surname>Meyer</surname> <given-names>K</given-names></string-name>, <etal>…</etal> <string-name><surname>Coutinho-Budd</surname> <given-names>J.</given-names></string-name></person-group> <article-title>Glia multitask to compensate for neighboring glial cell dysfunction</article-title>. <source>bioRxiv</source>. <year>2024</year> <pub-id pub-id-type="doi">10.1101/2024.09.06.611719</pub-id>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vieira</surname>, <given-names>C. R.</given-names></string-name>, <string-name><surname>Munoz-Olaya</surname>, <given-names>J. M.</given-names></string-name>, <string-name><surname>Sot</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jiménez-Baranda</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Izquierdo-Useros</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Abad</surname>, <given-names>J. L.</given-names></string-name>, <etal>…</etal> <string-name><surname>Goñi</surname>, <given-names>F. M.</given-names></string-name></person-group> (<year>2010</year>). <article-title>Dihydrosphingomyelin impairs HIV-1 infection by rigidifying liquid-ordered membrane domains</article-title>. <source>Chemistry &amp; biology</source>, <volume>17</volume>(<issue>7</issue>), <fpage>766</fpage>–<lpage>775</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hernández-Tiedra</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Fabrias</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Dávila</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Salanueva</surname>, <given-names>I. J.</given-names></string-name>, <string-name><surname>Casas</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Montes</surname>, <given-names>L. R.</given-names></string-name>, <etal>…</etal> <string-name><surname>Velasco</surname>, <given-names>G.</given-names></string-name></person-group> (<year>2016</year>). <article-title>Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization</article-title>. <source>Autophagy</source>, <volume>12</volume>(<issue>11</issue>), <fpage>2213</fpage>–<lpage>2229</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aggarwal</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Yurlova</surname>, <given-names>L.</given-names></string-name>, &amp; <string-name><surname>Simons</surname>, <given-names>M</given-names></string-name></person-group>. (<year>2011</year>). <article-title>Central nervous system myelin: structure, synthesis and assembly</article-title>. <source>Trends in cell biology</source>, <volume>21</volume>(<issue>10</issue>), <fpage>585</fpage>–<lpage>593</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailey</surname>, <given-names>A. P.</given-names></string-name>, <string-name><surname>Koster</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Guillermier</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Hirst</surname>, <given-names>E. M.</given-names></string-name>, <string-name><surname>MacRae</surname>, <given-names>J. I.</given-names></string-name>, <string-name><surname>Lechene</surname>, <given-names>C. P.</given-names></string-name>, <etal>…</etal> <string-name><surname>Gould</surname>, <given-names>A. P.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Antioxidant role for lipid droplets in a stem cell niche of Drosophila</article-title>. <source>Cell</source>, <volume>163</volume>(<issue>2</issue>), <fpage>340</fpage>–<lpage>353</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Sandoval</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Yamamoto</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Jaiswal</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Sanz</surname>, <given-names>E.</given-names></string-name>, <etal>…</etal> <string-name><surname>Bellen</surname>, <given-names>H. J.</given-names></string-name></person-group> (<year>2015</year>). <article-title>Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration</article-title>. <source>Cell</source>, <volume>160</volume>(<issue>1</issue>), <fpage>177</fpage>–<lpage>190</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>MacKenzie</surname>, <given-names>K. R.</given-names></string-name>, <string-name><surname>Putluri</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Maletić-Savatić</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Bellen</surname>, <given-names>H. J</given-names></string-name></person-group>. (<year>2017</year>). <article-title>The glia-neuron lactate shuttle and elevated ROS promote lipid synthesis in neurons and lipid droplet accumulation in glia via APOE/D</article-title>. <source>Cell metabolism</source>, <volume>26</volume>(<issue>5</issue>), <fpage>719</fpage>–<lpage>737</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marshall</surname>, <given-names>L. L.</given-names></string-name>, <string-name><surname>Stimpson</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>Hyland</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Coorssen</surname>, <given-names>J. R.</given-names></string-name>, &amp; <string-name><surname>Myers</surname>, <given-names>S. J</given-names></string-name></person-group>. (<year>2014</year>). <article-title>Increased lipid droplet accumulation associated with a peripheral sensory neuropathy</article-title>. <source>Journal of chemical biology</source>, <volume>7</volume>, <fpage>67</fpage>–<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname>, <given-names>B. C.</given-names></string-name>, <string-name><surname>Walsh</surname>, <given-names>A. E.</given-names></string-name>, <string-name><surname>Kluemper</surname>, <given-names>J. C.</given-names></string-name>, &amp; <string-name><surname>Johnson</surname>, <given-names>L. A</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Lipid droplets in neurodegenerative disorders</article-title>. <source>Frontiers in neuroscience</source>, <volume>14</volume>, <fpage>742</fpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marschallinger</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Iram</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Zardeneta</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>S. E.</given-names></string-name>, <string-name><surname>Lehallier</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Haney</surname>, <given-names>M. S.</given-names></string-name>, <etal>…</etal> <string-name><surname>Wyss-Coray</surname>, <given-names>T.</given-names></string-name></person-group> (<year>2020</year>). <article-title>Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain</article-title>. <source>Nature neuroscience</source>, <volume>23</volume>(<issue>2</issue>), <fpage>194</fpage>–<lpage>208</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bischof</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Björklund</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Furger</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Schertel</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Taipale</surname>, <given-names>J.</given-names></string-name>, &amp; <string-name><surname>Basler</surname>, <given-names>K</given-names></string-name></person-group>. (<year>2013</year>). <article-title>A versatile platform for creating a comprehensive UAS-ORFeome library in <italic>Drosophila</italic></article-title>. <source>Development</source>, <volume>140</volume>(<issue>11</issue>), <fpage>2434</fpage>–<lpage>2442</lpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choi</surname>, <given-names>H. M.</given-names></string-name>, <string-name><surname>Schwarzkopf</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Fornace</surname>, <given-names>M. E.</given-names></string-name>, <string-name><surname>Acharya</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Artavanis</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Stegmaier</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cunha</surname>, <given-names>A.</given-names></string-name>, &amp; <string-name><surname>Pierce</surname>, <given-names>N. A</given-names></string-name></person-group>. (<year>2018</year>). <article-title>Third-generation in situ hybridization chain reaction: multiplexed, quantitative, sensitive, versatile, robust</article-title>. <source>Development</source>, <volume>145</volume>(<issue>12</issue>), <fpage>dev165753</fpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lacin</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>H. M.</given-names></string-name>, <string-name><surname>Long</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Singer</surname>, <given-names>R. H.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>T.</given-names></string-name>, &amp; <string-name><surname>Truman</surname>, <given-names>J. W</given-names></string-name></person-group>. (<year>2019</year>). <article-title>Neurotransmitter identity is acquired in a lineage-restricted manner in the Drosophila CNS</article-title>. <source>eLife</source>, <volume>8</volume>, <elocation-id>e43701</elocation-id>. <pub-id pub-id-type="doi">10.7554/eLife.43701</pub-id></mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Duckhorn</surname>, <given-names>J. C.</given-names></string-name>, <string-name><surname>Junker</surname>, <given-names>I. P.</given-names></string-name>, <string-name><surname>Ding</surname>, <given-names>Y.</given-names></string-name>, &amp; <string-name><surname>Shirangi</surname>, <given-names>T. R</given-names></string-name></person-group>. (<year>2022</year>). <chapter-title>Combined in situ hybridization chain reaction and immunostaining to visualize gene expression in whole-mount <italic>Drosophila</italic> central nervous systems</chapter-title>. In <person-group person-group-type="editor"><string-name><surname>Yamamoto</surname>, <given-names>D.</given-names></string-name></person-group> <source>Behavioral Neurogenetics</source> (pp. <fpage>1</fpage>–<lpage>14</lpage>). <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer US</publisher-name>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patel</surname>, <given-names>N. H</given-names></string-name></person-group>. (<year>1994</year>). <article-title>Imaging neuronal subsets and other cell types in whole-mount <italic>Drosophila</italic> embryos and larvae using antibody probes</article-title>. <source>Methods in cell biology</source>, <volume>44</volume>, <fpage>445</fpage>–<lpage>487</lpage>.</mixed-citation></ref>
<ref id="c77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Truman</surname>, <given-names>J. W.</given-names></string-name>, <string-name><surname>Schuppe</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Shepherd</surname>, <given-names>D.</given-names></string-name>, &amp; <string-name><surname>Williams</surname>, <given-names>D. W</given-names></string-name></person-group>. (<year>2004</year>). <article-title>Developmental architecture of adult-specific lineages in the ventral CNS of Drosophila</article-title>. <source>Development</source>, <volume>131</volume>(<issue>20</issue>), <fpage>5167</fpage>–<lpage>5184</lpage></mixed-citation></ref>
<ref id="c78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cho</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Schwaiger-Haber</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Naser</surname>, <given-names>F. J.</given-names></string-name>, <string-name><surname>Stancliffe</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Sindelar</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Patti</surname>, <given-names>G. J</given-names></string-name></person-group>. (<year>2021</year>). <article-title>Targeting unique biological signals on the fly to improve MS/MS coverage and identification efficiency in metabolomics</article-title>. <source>Analytica chimica acta</source>, <volume>1149</volume>, <fpage>338210</fpage>.</mixed-citation></ref>
<ref id="c79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adams</surname>, <given-names>K. J.</given-names></string-name>, <string-name><surname>Pratt</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Bose</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Dubois</surname>, <given-names>L. G.</given-names></string-name>, <string-name><surname>St. John-Williams</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Perrott</surname>, <given-names>K. M.</given-names></string-name>, <etal>…</etal> <collab>Alzheimer’s Disease Metabolomics Consortium</collab></person-group>. (<year>2020</year>). <article-title>Skyline for small molecules: a unifying software package for quantitative metabolomics</article-title>. <source>Journal of proteome research</source>, <volume>19</volume>(<issue>4</issue>), <fpage>1447</fpage>–<lpage>1458</lpage>.</mixed-citation></ref>
<ref id="c80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Davis</surname>, <given-names>C. A.</given-names></string-name>, <string-name><surname>Schlesinger</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Drenkow</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zaleski</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Jha</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Batut</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chaisson</surname>, <given-names>M.</given-names></string-name>, &amp; <string-name><surname>Gingeras</surname>, <given-names>T. R</given-names></string-name></person-group>. (<year>2013</year>). <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>, <volume>29</volume>(<issue>1</issue>), <fpage>15</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Smyth</surname>, <given-names>G. K.</given-names></string-name>, &amp; <string-name><surname>Shi</surname>, <given-names>W</given-names></string-name></person-group>. (<year>2014</year>). <article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title>. <source>Bioinformatics</source>, <volume>30</volume>(<issue>7</issue>), <fpage>923</fpage>–<lpage>930</lpage>.</mixed-citation></ref>
<ref id="c82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Patro</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Duggal</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Love</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>Irizarry</surname>, <given-names>R. A.</given-names></string-name>, &amp; <string-name><surname>Kingsford</surname>, <given-names>C</given-names></string-name></person-group>. (<year>2017</year>). <article-title>Salmon provides fast and bias-aware quantification of transcript expression</article-title>. <source>Nature methods</source>, <volume>14</volume>(<issue>4</issue>), <fpage>417</fpage>–<lpage>419</lpage>.</mixed-citation></ref>
<ref id="c83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname>, <given-names>M. I.</given-names></string-name>, <string-name><surname>Huber</surname>, <given-names>W.</given-names></string-name>, &amp; <string-name><surname>Anders</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome biology</source>, <volume>15</volume>(<issue>12</issue>), <fpage>1</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langfelder</surname>, <given-names>P.</given-names></string-name>, &amp; <string-name><surname>Horvath</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2008</year>). <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC bioinformatics</source>, <volume>9</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99344.2.sa4</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bellen</surname>
<given-names>Hugo J</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Baylor College of Medicine</institution>
</institution-wrap>
<city>Houston</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This study on the loss of DEGS1 in the developing larval brain <bold>convincingly</bold> shows the accumulation of dihydroceramide in the CNS which induces severe alterations in the morphology of glial subtypes as well as a reduction in glial number. The localization of DEGS1/ifc primarily to the ER is also <bold>compelling</bold> and interesting, and the loss of DEGS1/ifc clearly drives ER expansion and reduces the levels of TGs. This is an <bold>important</bold> contribution to the role of lipid metabolism in neural development and disease.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99344.2.sa3</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>Zhu et al., investigate the cellular defects in glia as a result of loss in DEGS1/ifc encoding the dihydroceramide desaturase. Using the strength of Drosophila and its vast genetic toolkit, they find that DEGS1/ifc is mainly expressed in glia and it's loss leads to profound neurodegeneration. This supports a role for DEGS1 in the developing larval brain as it safeguards proper CNS development. Loss of DEGS1/ifc leads to dihydroceramide accumulation in the CNS and induces alteration in the morphology of glial subtypes and a reduction in glial number. Cortex and ensheathing glia appeared swollen and accumulated internal membranes. Astrocyte-glia on the other hand displayed small cell bodies, reduced membrane extension and disrupted organization in the dorsal ventral nerve cord. They also found that DEGS1/ifc localizes primarily to the ER. Interestingly, the authors observed that loss of DEGS1/ifc drives ER expansion and reduced TGs and lipid droplet numbers. No effect on PC and PE and a slight increase in PS.</p>
<p>The conclusions of this paper are well supported by the data.</p>
<p>Strengths:</p>
<p>This is an interesting study that provides new insight into the role of ceramide metabolism in neurodegeneration.</p>
<p>The strength of the paper is the generation of LOF lines, the insertion of transgenes and the use of the UAS-GAL4/GAL80 system to assess the cell-autonomous effect of DEGS1/ifc loss in neurons and different glial subtypes during CNS development.</p>
<p>The imaging, immunofluorescence staining and EM of the larval brain and the use of the optical lobe and the nerve cord as a readout are very robust and nicely done.</p>
<p>Drosophila is a difficult model to perform core biochemistry and lipidomics, but the authors used the whole larvae and CNS to uncover global changes in mRNA levels related to lipogenesis and the unfolded protein responses, as well as specific lipid alterations upon DEGS1/ifc loss.</p>
<p>Weaknesses:</p>
<p>No major weaknesses identified.</p>
<p>Minor point: The authors performed lipidomics and RTqPCR on whole larvae and larval CNS which does not inform of any cell type-specific effects. Performing single-cell RNAseq on larval brains to tease apart the cell-type specific effect of DEGS1/ifc loss would be interesting to explore the future, but beyond the scope of the current study.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99344.2.sa2</article-id>
<title-group>
<article-title>Reviewer #2 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The manuscript by Zhu et al. describes phenotypes associated with the loss of the gene ifc using a Drosophila model. The authors suggest their findings are relevant to understanding the molecular underpinnings of a neurodegenerative disorder, HLD-18, which is caused by mutations in the human ortholog of ifc, DEGS1.</p>
<p>The work begins with the authors describing the role for ifc during fly larval brain development, demonstrating its function in regulating developmental timing, brain size, and ventral nerve cord elongation. Further mechanistic examination revealed that loss of ifc leads to depleted cellular ceramide levels as well as dihydroceramide accumulation, eventually causing defects in ER morphology and function. Importantly, the authors showed that ifc is predominantly expressed in glia and is critical for maintaining appropriate glial cell numbers and morphology. Many of the key phenotypes caused by the loss of fly ifc can be rescued by overexpression of human DEGS1 in glia, demonstrating the conserved nature of these proteins as well as the pathways they regulate. Interestingly, the authors discovered that the loss of lipid droplet formation in ifc mutant larvae within the cortex glia, presumably driving the deficits in glial wrapping around axons and subsequent neurodegeneration, potentially shedding light on mechanisms of HLD-18 and related disorders.</p>
<p>Strengths:</p>
<p>Overall, the manuscript is thorough in its analysis of ifc function and mechanism. The data images are high quality, the experiments are well controlled, and the writing is clear. There are, however, some concerns that need to be addressed prior to publication.</p>
<p>Weaknesses:</p>
<p>The authors adequately addressed the previously indicated weaknesses, and no new weaknesses have been identified.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99344.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this manuscript, the authors report three novel ifc alleles: ifc[js1], ifc[js2], and ifc[js3]. ifc[js1] and ifc[js2] encode missense mutations, V276D and G257S, respectively. ifc[js3] encodes a nonsense mutation, W162*. These alleles exhibit multiple phenotypes, including delayed progression to the late-third larval instar stage, reduced brain size, elongation of the ventral nerve cord, axonal swelling, and lethality during late larval or early pupal stages.</p>
<p>Further characterization of these alleles the authors reveals that ifc is predominantly expressed in glia and localizes to the endoplasmic reticulum (ER). The expression of ifc gene governs glial morphology and survival. Expression of fly ifc cDNA or human DEGS1 cDNA specifically in glia, but not neurons, rescues the CNS phenotypes of ifc mutants, indicating a crucial role for ifc in glial cells and its evolutionary conservation. Loss of ifc results in ER expansion and loss of lipid droplets in cortex glia. Additionally, loss of ifc leads to ceramide depletion and accumulation of dihydroceramide. Moreover, it increases the saturation levels of triacylglycerols and membrane phospholipids. Finally, the reduction of dihydroceramide synthesis suppresses the CNS phenotypes associated with ifc mutations, indicating the key role of dihydroceramide in causing ifc LOF defects.</p>
<p>Strengths:</p>
<p>This manuscript unveils several intriguing and novel phenotypes of ifc loss-of-function in glia. The experiments are meticulously planned and executed, with the data strongly supporting their conclusions.</p>
</body>
</sub-article>
<sub-article id="sa4" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99344.2.sa0</article-id>
<title-group>
<article-title>Author Response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yuqing</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cho</surname>
<given-names>Kevin</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lacin</surname>
<given-names>Haluk</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2468-9618</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Yi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>DiPaola</surname>
<given-names>Jose T</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Beth A</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patti</surname>
<given-names>Gary J</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Skeath</surname>
<given-names>James B</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #1 (Public Review):</bold></p>
<p><bold>Summary</bold>: Zhu et al., investigate the cellular defects in glia as a result of loss in DEGS1/ifc encoding the dihydroceramide desaturase. Using the strength of Drosophila and its vast genetic toolkit, they find that DEGS1/ifc is mainly expressed in glia and its loss leads to profound neurodegeneration. This supports a role for DEGS1 in the developing larval brain as it safeguards proper CNS development. Loss of DEGS1/ifc leads to dihydroceramide accumulation in the CNS and induces alteration in the morphology of glial subtypes and a reduction in glial number. Cortex and ensheathing glia appeared swollen and accumulated internal membranes. Astrocyte-glia on the other hand displayed small cell bodies, reduced membrane extension and disrupted organization in the dorsal ventral nerve cord. They also found that DEGS1/ifc localizes primarily to the ER. Interestingly, the authors observed that loss of DEGS1/ifc drives ER expansion and reduced TGs and lipid droplet numbers. No effect on PC and PE and a slight increase in PS.</p>
<p>The conclusions of this paper are well supported by the data. The study could be further strengthened by a few additional controls and/or analyses.</p>
<p>Strengths:</p>
<p>This is an interesting study that provides new insight into the role of ceramide metabolism in neurodegeneration.</p>
<p>The strength of the paper is the generation of LOF lines, the insertion of transgenes and the use of the UAS-GAL4/GAL80 system to assess the cell-autonomous effect of DEGS1/ifc loss in neurons and different glial subtypes during CNS development.</p>
<p>The imaging, immunofluorescence staining and EM of the larval brain and the use of the optical lobe and the nerve cord as a readout are very robust and nicely done.</p>
<p>Drosophila is a difficult model to perform core biochemistry and lipidomics but the authors used the whole larvae and CNS to uncover global changes in mRNA levels related to lipogenesis and the unfolded protein responses as well as specific lipid alterations upon DEGS1/ifc loss.</p>
<p>Weaknesses:</p>
<p>(1) The authors performed lipidomics and RTqPCR on whole larvae and larval CNS from which it is impossible to define the cell type-specific effects. Ideally, this could be further supported by performing single cell RNAseq on larval brains to tease apart the cell-type specific effect of DEGS1/ifc loss.</p>
</disp-quote>
<p>We agree that using scRNAseq or pairing FACS-sorting of individual glial subtypes with bulk RNAseq would help tease apart the cell-type specific effects of DEGS1/ifc loss on glial cells. At this time, however, this approach extends beyond the scope of the current paper and means of the lab.</p>
<disp-quote content-type="editor-comment">
<p>(2) It's clear from the data that the accumulation of dihydroceramide in the ER triggers ER expansion but it remains unclear how or why this happens. Additionally, the authors assume that, because of the reduction in LD numbers, that the source of fatty acids comes from the LDs. But there is no data testing this directly.</p>
</disp-quote>
<p>As CERT, the protein that transports ceramide from the ER to the Golgi, is far more efficient at transporting ceramide than dihydroceramide, we speculate that dihydroceramide accumulates in the ER due to inefficient transport from the ER to the Golgi by CERT. We state this model more explicitly in the results under the subheading “Reduction of dihydroceramide synthesis suppresses the ifc CNS phenotype”.</p>
<p>We agree with the point on lipid droplet. We observe a correlation, not a causation, between reduction of lipid droplets and a large expansion of ER membrane. We have tried to clarify the text in the last paragraph of the discussion to make this point more clearly. See also response to reviewer 2 point 3.</p>
<disp-quote content-type="editor-comment">
<p>(3) The authors performed a beautiful EMS screen identifying several LOF alleles in <italic>ifc</italic>. However, the authors decided to only use KO/ifcJS3. The paper could be strengthened if the authors could replicate some of the key findings in additional fly lines.</p>
</disp-quote>
<p>We agree. We replicated the observed cortex glia swelling, ER expansion in cortex glia, and observed increase in neuronal cell death markers in late-third instar larvae mutant for either the ifcjs1 or ifcjs2 allele. These data are now provided as Supplementary Figure 7.</p>
<disp-quote content-type="editor-comment">
<p>(4) The authors use M{3xP3-RFP.attP}ZH-51D transgene as a general glial marker. However, it would be advised to show the % overlap between the glial marker and the RFP since a lot of cells are green positive but not per se RFP positive and vice versa.</p>
</disp-quote>
<p>We visually reexamined the expression of the 3xP3 RFP transgene relative to FABP labeling for cortex glia, Ebony for astrocyte-like glia, and the Myr-GFP transgene driven by glial-subtype specific GAL4 driver lines for perineurial, subperineurial, and ensheathing glia. We note that RFP localizes to the nucleus cytoplasm while FABP and Ebony localize to the cytoplasm and Myr-GFP to the cell membrane. Thus, an observed lack of overlap of expression between RFP and the other markers can arise to differential localization of the two markers in the same cells (see, for example, Fig. S2D where Myr-GFP expression in the nuclear envelope encircles that of RFP in the nucleus. Through visual inspection of five larval-brain complexes for each glial subtype marker, we found that essentially all cortex, SPG, and ensheathing glia expressed RFP. Similarly, nearly all astrocyte-like glia also expressed RFP, but they expressed RFP at significantly lower levels than that observed for cortex, SPG, or ensheathing glia. This analysis also confirmed that most perineurial glia do not express RFP. The 3xP3 M{3xP3-RFP.attP}ZH-51D transgene then labels most glia in the Drosophila CNS. We have added text to Supplementary Figure 2 noting the above observations as to which glial cells express RFP.</p>
<disp-quote content-type="editor-comment">
<p>(5) The authors indicate that other 3xP3 RFP and GFP transgenes at other genomic locations also label most glia in the CNS. Do they have a preferential overlap with the different glial subtypes?</p>
</disp-quote>
<p>We assessed three different types of 3xP3 RFP and GFP transgenes: M{3xP3RFP.attp} transgenes (n=4), Mi{GFP[E.3xP3]=ET1} transgenes (n=3), and</p>
<p>Tl{GFP[3xP3.cLa]=CRIMIC.TG4} transgenes (n&gt;6). All labeled cortex glia, but different lines exhibited differential labeling of astrocyte and ensheathing glia. These data are now included as Supplementary Figure 3_._</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public Review):</bold></p>
<p>Summary:</p>
<p>The manuscript by Zhu et al. describes phenotypes associated with the loss of the gene ifc using a Drosophila model. The authors suggest their findings are relevant to understanding the molecular underpinnings of a neurodegenerative disorder, HLD-18, which is caused by mutations in the human ortholog of ifc, DEGS1.</p>
<p>The work begins with the authors describing the role for ifc during fly larval brain development, demonstrating its function in regulating developmental timing, brain size, and ventral nerve cord elongation. Further mechanistic examination revealed that loss of ifc leads to depleted cellular ceramide levels as well as dihydroceramide accumulation, eventually causing defects in ER morphology and function. Importantly, the authors showed that ifc is predominantly expressed in glia and is critical for maintaining appropriate glial cell numbers and morphology. Many of the key phenotypes caused by the loss of fly ifc can be rescued by overexpression of human DEGS1 in glia, demonstrating the conserved nature of these proteins as well as the pathways they regulate. Interestingly, the authors discovered that the loss of lipid droplet formation in ifc mutant larvae within the cortex glia, presumably driving the deficits in glial wrapping around axons and subsequent neurodegeneration, potentially shedding light on mechanisms of HLD-18 and related disorders.</p>
<p>Strengths:</p>
<p>Overall, the manuscript is thorough in its analysis of ifc function and mechanism. The data images are high quality, the experiments are well controlled, and the writing is clear.</p>
<p>Weaknesses:</p>
<p>(1) The authors clearly demonstrated a reduction in number of glia in the larval brains of ifc mutant flies. What remains unclear is whether ifc loss leads to glial apoptosis or a failure for glia to proliferate during development. The authors should distinguish between these two hypotheses using apoptotic markers and cell proliferation markers in glia.</p>
</disp-quote>
<p>To address this point, we used phospho-histone H3 to assess mitotic index in the thoracic CNS of wild-type versus ifc mutant late third instar larvae and found a mild, but significant reduction in mitotic index in ifc mutant relative to wild-type nerve cords. We also assessed the ability of glial-specific expression of the potent anti-apoptotic gene p35 to rescue the observed loss of cortex glia phenotype in the thoracic region of the CNS of otherwise ifc mutant larvae and observed a clear increase in cortex glia in the presence versus the absence of glial-specific p35 expression (p&lt;3 x 10-4). These data are now provided as Supplementary Figure S8 in the paper and referred to on page 8.</p>
<disp-quote content-type="editor-comment">
<p>(2) It is surprising that human DEGS1 expression in glia rescues the noted phenotypes despite the different preference for sphingoid backbone between flies and mammals. Though human DEGS1 rescued the glial phenotypes described, can animal lethality be rescued by glial expression of human DEGS1? Are there longer-term effects of loss of ifc that cannot be compensated by the overexpression of human DEGS1 in glia (age-dependent neurodegeneration, etc.)?</p>
</disp-quote>
<p>We note explicitly that while glial expression of human DEGS1 does provide rescuing activity, it only partially rescues the ifc mutant CNS phenotype in contrast to glial expression of Drosophila ifc, which fully rescues this phenotype. Thus, the relative activity of human DEGS1 is far below that of Drosophila ifc when assayed in flies. To quantify the functional difference between the two transgenes, we assessed the ability of glial expression of fly ifc or of human DEGS1 to rescue the lethality of otherwise ifc mutant larvae: Glial expression of ifc was sufficient to rescue the adult viability of 57.9% of ifc mutant flies based on expected Mendelian ratios (n=2452), whereas glial expression of DEGS1 was sufficient to rescue just 3.9% of ifc mutant flies (n=1303), uncovering a ~15-fold difference in the ability of the two transgenes to rescue the lethality of otherwise ifc mutant flies. In the absence of either transgene, no ifc mutant larvae reached adulthood (n=1030). These data are now provided in the text on page 9 of the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p>(3) The mechanistic link between the loss of ifc and lipid droplet defects is missing. How do defects in ceramide metabolism alter triglyceride utilization and storage? While the author's argument that the loss of lipid droplets in larval glia will lead to defects in neuronal ensheathment, a discussion of how this is linked to ceramides needs to be added.</p>
</disp-quote>
<p>We have revised the text to address this point. We speculate that the apparent increased demand for membrane phospholipid synthesis may drive the depletion of lipid droplets, providing a link to ifc function and ceramides. Below we provide the rewritten last paragraph; the underlined section is the new text.</p>
<p>“The expansion of ER membranes coupled with loss of lipid droplets in ifc mutant larvae suggests that the apparent demand for increased membrane phospholipid synthesis may drive lipid droplet depletion, as lipid droplet catabolism can release free fatty acids to serve as substrates for lipid synthesis. At some point, the depletion of lipid droplets, and perhaps free fatty acids as well, would be expected to exhaust the ability of cortex glia to produce additional membrane phospholipids required for fully enwrapping neuronal cell bodies. Under wild-type conditions, many lipid droplets are present in cortex glia during the rapid phase of neurogenesis that occurs in larvae. During this phase, lipid droplets likely support the ability of cortex glia to generate large quantities of membrane lipids to drive membrane growth needed to ensheathe newly born neurons. Supporting this idea, lipid droplets disappear in the adult Drosophila CNS when neurogenesis is complete and cortex glia remodeling stops. We speculate that lipid droplet loss in ifc mutant larvae contributes to the inability of cortex glia to enwrap neuronal cell bodies. Prior work on lipid droplets in flies has focused on stress-induced lipid droplets generated in glia and their protective or deleterious roles in the nervous system. Work in mice and humans has found that more lipid droplets are often associated with the pathogenesis of neurodegenerative diseases, but our work correlates lipid droplet loss with CNS defects. In the future, it will be important to determine how lipid droplets impact nervous system development and disease.”</p>
<disp-quote content-type="editor-comment">
<p>(4) On page 10, the authors use the words &quot;strong&quot; and &quot;weak&quot; to describe where ifc is expressed. Since the use of T2A-GAL4 alleles in examining gene expression is unable to delineate the amount of gene expression from a locus, the terms &quot;broad&quot; and &quot;sparse&quot; labeling (or similar terms) should be used instead.</p>
</disp-quote>
<p>The ifc T2A-GAL4 insert in the ifc locus reports on the transcription of the gene. We agree that GAL4 system will not reflect amount of gene expression differences when the expression levels are not dramatically different. However, when the expression levels differ dramatically, as in our case, GAL4 system can reflect this difference in the expression of a reporter gene.  We reworded this section to suggest that ifc is transcribed at higher levels in glia as compared to neurons. We can’t use sparse or broad, as ifc is expressed in all, or at least in most, glia and neurons. The new text is as follows:” Using this approach, we observed strong nRFP expression in all glial cells (Figures 4D and S10A) and modest nRFP expression in all neurons (Figures 4E and S10B), suggesting ifc is transcribed at higher levels in glial cells than neurons in the larval CNS.”</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public Review):</bold></p>
<p>Summary:</p>
<p>In this manuscript, the authors report three novel ifc alleles: ifc[js1], ifc[js2], and ifc[js3]. ifc[js1] and ifc[js2] encode missense mutations, V276D and G257S, respectively. ifc[js3] encodes a nonsense mutation, W162*. These alleles exhibit multiple phenotypes, including delayed progression to the late-third larval instar stage, reduced brain size, elongation of the ventral nerve cord, axonal swelling, and lethality during late larval or early pupal stages.</p>
<p>Further characterization of these alleles the authors reveals that ifc is predominantly expressed in glia and localizes to the endoplasmic reticulum (ER). The expression of ifc gene governs glial morphology and survival. Expression of fly ifc cDNA or human DEGS1 cDNA specifically in glia, but not neurons, rescues the CNS phenotypes of ifc mutants, indicating a crucial role for ifc in glial cells and its evolutionary conservation. Loss of ifc results in ER expansion and loss of lipid droplets in cortex glia. Additionally, loss of ifc leads to ceramide depletion and accumulation of dihydroceramide. Moreover, it increases the saturation levels of triacylglycerols and membrane phospholipids. Finally, the reduction of dihydroceramide synthesis suppresses the CNS phenotypes associated with ifc mutations, indicating the key role of dihydroceramide in causing ifc LOF defects.</p>
<p>Strengths:</p>
<p>This manuscript unveils several intriguing and novel phenotypes of ifc loss-of-function in glia. The experiments are meticulously planned and executed, with the data strongly supporting their conclusions.</p>
<p>Weaknesses:</p>
<p>I didn't find any obvious weakness.</p>
<p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p>
<p>Additional minor comments below:</p>
<p>(1) The authors state that TGs are the building blocks of membrane phospholipids. This is not exactly true. The breakdown of TGs can result in free FAs which can be used for membrane phospholipid synthesis. Also, membrane phospholipids can also be generated from free FAs that were never in TGs.</p>
</disp-quote>
<p>To address this point, we have reworked a number of sentences in the text. On page 12 we reworded two small sections to the following:</p>
<p>“In the CNS, lipid droplets form primarily in cortex glia29 and are thought to contribute to membrane lipid synthesis through their catabolism into free fatty acids versus acting as an energy source in the brain.41 Consistent with the possibility that increased membrane lipid synthesis drives lipid droplet reduction, RNA-seq assays of dissected nerve cords revealed that loss of ifc drove transcriptional upregulation of genes that promote membrane lipid biogenesis”</p>
<p>As TG breakdown results in free fatty acids that can be used for membrane phospholipid synthesis, we asked if changes in TG levels and saturation were reflected in the levels or saturation of the membrane phospholipids phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS).</p>
<disp-quote content-type="editor-comment">
<p>(2) Figure 5J what does the dotted line indicate? Please specify in the figure legend or remove it.</p>
</disp-quote>
<p>We have added the following text in the figure legend: Dotted line indicates a log2 fold change of 0.5 in the treatment group compared to the control group.</p>
<disp-quote content-type="editor-comment">
<p>(3) The text for your graphs is hard to read. Please make the font larger.</p>
</disp-quote>
<p>We have increased font size to enhance the readability of the figures.</p>
<disp-quote content-type="editor-comment">
<p>(4) The authors mentioned that driving <italic>ifc</italic> expression in neurons rescues the phenotypes (ref 17). While the glial-specific role presented in this study is robust. I think some readers would appreciate some discussion of this study in light of the data presented here.</p>
</disp-quote>
<p>We have added the below text on page 10 to address this point.</p>
<p>“Results of our gene rescue experiments conflict with a prior study on ifc in which expression of ifc in neurons was found to rescue the ifc phenotype. In this context, we note that elav-GAL4 drives UASlinked transgene expression not just in neurons, but also in glia at appreciable levels, and thus needs to be paired with repo-GAL80 to restrict GAL4-mediated gene expression to neurons. Thus, “off-target” expression in glial cells may account for the discrepant results. It is, however, more difficult to reconcile how neuronal or glial expression of ifc would rescue the observed lethality of the ifc-KO chromosome given the presence additional lethal mutations in the 21E2 region of the second chromosome.”</p>
<disp-quote content-type="editor-comment">
<p>(5) While the analysis of fatty acid saturation is experimentally well done. I'm not really sure what the significance of this data is.</p>
</disp-quote>
<p>We included this information as a reference for future analysis of additional genes in the ceramide biogenesis pathway, as we expect that alteration of the levels and saturation levels of PE, PC, and PS in cell membranes may underlie key changes in the biophysical properties of glial cell membranes and their ability to enwrap or infiltrate their targets. Thus, we expect the significance of these data to grow as more work is done on additional members of the ceramide pathway in the nervous system in flies and other systems.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>(1) There is a typo at the top of page 11: &quot;internal membranes and fail enwrap neurons&quot; is missing the word &quot;to&quot; before &quot;enwrap&quot;</p>
</disp-quote>
<p>The typo was fixed.</p>
<disp-quote content-type="editor-comment">
<p>(2)  PMID: 36718090 should be included in the discussion of SPT and ORMDL complex in human disease.</p>
</disp-quote>
<p>The reference was added.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p>
<p>In this manuscript, the authors report three novel ifc alleles: ifc[js1], ifc[js2], and ifc[js3]. ifc[js1] and ifc[js2] encode missense mutations, V276D and G257S, respectively. ifc[js3] encodes a nonsense mutation, W162*. These alleles exhibit multiple phenotypes, including delayed progression to the late-third larval instar stage, reduced brain size, elongation of the ventral nerve cord, axonal swelling, and lethality during late larval or early pupal stages.</p>
<p>Further characterization of these alleles the authors reveals that ifc is predominantly expressed in glia and localizes to the endoplasmic reticulum (ER). The expression of ifc gene governs glial morphology and survival. Expression of fly ifc cDNA or human DEGS1 cDNA specifically in glia, but not neurons, rescues the CNS phenotypes of ifc mutants, indicating a crucial role for ifc in glial cells and its evolutionary conservation. Loss of ifc results in ER expansion and loss of lipid droplets in cortex glia. Additionally, loss of ifc leads to ceramide depletion and accumulation of dihydroceramide. Moreover, it increases the saturation levels of triacylglycerols and membrane phospholipids. Finally, the reduction of dihydroceramide synthesis suppresses the CNS phenotypes associated with ifc mutations, indicating the key role of dihydroceramide in causing ifc LOF defects.</p>
<p>In summary, this manuscript unveils several intriguing and novel phenotypes of ifc loss-of-function in glia. The experiments are meticulously planned and executed, with the data strongly supporting their conclusions. I have no additional comments and fully support the publication of this manuscript in eLife.</p>
</disp-quote>
<p>The authors also note that they added one paragraph to the discussion that addresses the possibility that the increased detection of cell death markers could arise due to the inability of glial cells to remove cellular debris. The text of this paragraph is provided below:</p>
<p>We note that cortex glia are the major phagocytic cell of the CNS and phagocytose neurons targeted for apoptosis as part of the normal developmental process.23-26  Thus, while we favor the model that ifc triggers neuronal cell death due to glial dysfunction, it is also possible that increased detection of dying neurons arises due at least in part to a decreased ability of cortex glia to clear dying neurons from the CNS. At present, the large number of neurons that undergo developmentally programmed cell death combined with the significant disruption to brain and ventral nerve cord morphology caused by loss of ifc function render this question difficult to address.Additional evidence does, however, support the idea that loss of ifc function drives excess neuronal cell death: Clonal analysis in the fly eye reveals that loss of ifc drives photoreceptor neuron degeneration17, indicating that loss of ifc function drives neuronal cell death; cortex-glia specific depletion of CPES, which acts downstream of ifc, disrupts neuronal function and induces photosensitive epilepsy in flies59, indicating that genes in the ceramide pathway can act nonautonomously in glia to regulate neuronal function; recent genetic studies reveal that other glial cells can compensate for impaired cortex glial cell function by phagocytosing dying neurons62, and we observe that the cell membranes of subperineurial glia enwrap dying neurons in ifc mutant larvae (Fig. S14), consistent with similar compensation occurring in this background, and in humans, loss of function mutations in DEGS1 cause neurodegeneration.7-9 Clearly, future work is required to address this question for ifc/DEGS1 and perhaps other members of the ceramide biogenesis pathway</p>
</body>
</sub-article>
</article>